CURRICULUM VITAE

LAI-SHAN TAM

PROFESSOR

DEPARTMENT OF MEDICINE AND THERAPEUTICS

THE CHINESE UNIVERSITY OF HONG KONG

SHATIN, NEW TERRITORIES

HONG KONG

|  |  |
| --- | --- |
| AWARDS   1. C. W. Wong Scholarship in Medicine, The Chinese University of Hong Kong 1991 2. Ko Ho Ning Scholarship in Medicine, The Chinese University of Hong Kong 1992 3. Young Physician’s Training Scholarship, Department of Medicine and Therapeutics, The Chinese University of Hong Kong 1997 4. Ian Watson Award of the Canadian Rheumatology Association (CRA) Annual Meeting, Banff, Canada 1999 5. Annual Ogryzlo Day Research Competition award, Toronto, Canada 1999 6. Distinguished Research Paper Award for Young Investigators and Research Team Award 2005, and 2009 awarded by the Hong Kong College of Physicians. 7. Student Training & Campus Service Award 2007/2008, 2008/2009 awarded by the Conference & Research Grant Committee of Shaw College. 8. The 5th East Asian Group of Rheumatology (EAGOR) 2013 Young Investigator Award 9. Poster presentation Award on “Effects of Early Remission on Work Ability and Absenteeism in Early Rheumatoid Arthritis” in the category of “Advances in health, research and innovation”. Hospital Authority Convention 2016. 10. Best Performing Editor for the International Journal of Rheumatic Diseases Sept 2018 11. Top Editor for the International Journal of Rheumatic Diseases April 2019 12. EULAR Honorary Member 2019.   <https://www.med.cuhk.edu.hk/award-winning-research>  <https://www.med.cuhk.edu.hk/awards>   1. The Chinese University Rheumatology Research Center (CURRC), The Chinese University of Hong Kong has been selected as the APLAR Center of Excellence 2019.   Faculty website: <https://www.med.cuhk.edu.hk/awards>  Faculty Facebook: <https://www.facebook.com/CUHKMedicine/photos/a.514240978711707/1514228578712937/?type=3&theater>  Faculty twitter: <https://twitter.com/CUHKMedicine/status/1117648230567661570>   1. [**2018 APLAR axial spondyloarthritis treatment recommendations**](https://onlinelibrary.wiley.com/doi/full/10.1111/1756-185X.13510?elq_mid=43484&elq_cid=25579903&elqCampaignId=27757&utm_campaign=27757&utm_source=eloquaEmail&utm_medium=email&utm_content=Batch1-Email-FY20-Q3-R-DG-TopDownloaded-Authors-W26CS&elqTrack=true) received the top downloaded paper award between January 2018 and December 2019 by IJRD   RESEARCH GRANTS  **External competitive grant in the capacity of Principal Investigator**   * Project title: Cardiovascular risk profile of patients with psoriatic arthritis compared to controls.  Grant agency: Hong Kong Arthritis Foundation  * Awarded $30,000. * Year: 2007 * Project titled “Risk of active tuberculosis in patients with rheumatoid arthritis in Hong Kong”.  Grant agency: Research Fund for the Control of Infectious Diseases (RFCID)  * Awarded HK$73,416 * Year: 2008 * Project titled “In vivo assessment of bone microarchitecture in patients on chronic steroid therapy by high-resolution peripheral quantitative computed tomography and the finite method” * Grant agency: Hong Kong Research Grant Council (RGC) General Research Fund (GRF) * Ref no: 471010 * Total amount: HK$1,200,000 * Year: 6-10-2010 to 5-10-2013 * Effect of treat-to-target strategies aiming at remission compared with minimal disease activity on arterial stiffness in early rheumatoid arthritis - a randomized controlled study * Grant agency: Health and Health Services Research Fund (HHSRF) * Appl. No: 10110071 * Total amount: HK$659,422 * Duration: 1/12/2012-31/11/2016 * Vascular effects of achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) – a 2 year prospective cohort study * Grant agency: Health and Medical Research Fund (HMRF) * Appl. No: 01120496 * Total amount:HK$879,422 * Duration: 1/5/2014-30/4/2017  Advanced 3-D Bioimaging Technology for Enhancing Diagnostic Sensitivity of Fracture in Patients With Glucocorticoid-induced Osteoporosis  * Research Grant Council (RGC) General Research Fund (GRF) * Appl. No: 14113714 * Total amount:HK$947,992 * Duration: 1-10-2014 to 30-9-2016 * Effect of RANKL inhibition on healing of bone erosion in rheumatoid arthritis using HR-pQCT * Health and Medical Research Fund (HMRF) Appl. No: 04152616 (PA) * Total amount: HK$ 1,199,634 * Duration: 1 May 2017 – 30 Apr 2020   **Non-external competitive grant in the capacity of Principal Investigator**   * CUHK Direct grant 2007   Project title: One Gene Many Diseases – Study of the OCTN-OCTN2 oci in Chinese Patients with Autoimmune Diseases (AID) Grant agency: CUHK  * Awarded $78,250 * Year: 2007 * CUHK Direct grant 2008  Project entitled “Measurement of tumor necrosis factor α, leukotriene B4, and interleukin 8 in the exhaled breath condensate in rheumatic disease patients with active disease before and after commencement of immunosuppressants”.Grant agency: CUHKAwarded $40,000  * Year: 2008 * The Fellowship Grant from Janssen Pharmaceutica   Project title “The efficacy of methotrexate and infliximab in patients with earlier onset of rheumatoid arthritis: anti-cyclic citrullinated peptide, clinical and magnetic resonance imaging correlation”. Grant agency: Janssen PharmaceuticaAwarded HK$200,000  * Year: 2008 * CUHK Direct grant 2009.1.027   Project title “Function and expression profile of the nucleotide-binding and oligomerization domain (NOD)-2 receptors in systemic lupus erythematosus”   * Awarded: HK$30,000 * Year: 1/4/2010-31/3/2011 |  |

1. Immunopathological roles of the novel anti-inflammatory cytokines interleukin-36 in patients with systemic lupus erythematosus

* Grant agency: The Hong Kong Society of Rheumatology Project Fund 2013-2014
* Total amount: HK $ 80,000
* Duration: 1/1/2014-31/12/2014

1. Assessment of structure changes after 4 years on the second metacarpophalangeal joint in patients with psoriatic arthritis – a follow-up study using High-resolution peripheral quantitative CT (HR-pQCT)

* The Hong Kong Society of Rheumatology Project Fund 2016-2017
* Total amount: HK $ 100,000
* Duration: 1/6/2017- 31/5/2018

1. Effect of RANKL inhibition on healing of bone erosion in rheumatoid arthritis using HR-pQCT

* Health and Medical Research Fund (HMRF) Appl. No: 04152616 (PA)
* Total amount: HK$ 1,199,634
* Duration: 1 May 2017 – 30 Apr 2020

**External competitive grant in the capacity of Co- Investigator**

1. National Institute of Health (NIH) grant # 5 P01 AT002605

* Project title: Traditional Chinese Medicine for Osteoarthritis of the Knee (TCM-OAK): A dose escalation study
* Grant agency: NIH
* Awarded US$ 6,000,000
* Year: 2005-2010
* Percentage of contribution: This is a project in collaboration with the University of Maryland. There are altogether three projects and three supporting core. Our center is responsible for the recruitment of 40 out of the 100 patients in the phase II study.

2. Health and Health Services Research Grant (HHSRF) 2008-2009

* Project title: Comparison of Steroid and Non-steroidal anti-inflammatory drug Therapy in the Treatment of Acute Gout like Arthritis: A Multi-centre, Double-Blind, Randomized, Equivalence Trial”
* Grant agency: Health and Health Services Research Grant (HHSRF)
* Awarded HK$ 486,080
* Year: 2009
* Percentage of contribution: 10%, I am responsible for patient recruitment and management

4. The Hong Kong Society of Rheumatology Project Fund 2011-2012 (PI: Shuilian Yu)

* Project titled “RAGE: a new therapeutic target and biomarker of rheumatoid arthritis”
* Total amount: HK$80,000
* Duration: 01/10/2011 to 01/10/2012

5. The Hong Kong Society of Rheumatology Project Fund 2011-2012 (PI: Tracy Zhu)

* Project titled “Incident vertebral and non-vertebral fracture in female patients with systemic lupus erythematosus: a five-year longitudinal study”
* Total amount: HK$80,000
* Duration: 01/04/2012 to 30/09/2012

6. Health and Medical Research Fund (HMRF) Appl. No: 12130841

* PI: Prof Qin Ling
* Title : Volumetric Bone Mineral Density and Bone Microarchitecture: A New Population-based Reference Study with High Resolution peripheral Quantitative Computer Tomography
* Total amount: HK$ 996,216
* Duration: 1/4/2015 – 31/3/2017

1. Health and Medical Research Fund (HMRF) Appl. No: 02130686

* PI: Prof SHANG Qing
* Title : Non-invasive Assessment of Cardiovascular Reserve in Patients with Systemic Autoimmune Diseases
* Total amount: HK$ 833,148
* Duration: 28 July 2015 – 27 Jan 2017

1. The Hong Kong Society of Rheumatology Project Fund 2015-2016

* title “Plasma microRNAs targeting IL-33 as biomarkers to predict subclinical atherosclerosis in patients with early rheumatoid arthritis “
* Grant awarded: HK$100,000.
* PI: Dr. Shen Jiayun
* Expected start date: 1/1/2016- Expected end date: 31/12/2016

**Non-external competitive grant in the capacity of Principle Investigator**

1. CUHK Direct grant 2007

* Project title: One Gene Many Diseases – Study of the OCTN-OCTN2 oci in Chinese Patients with Autoimmune Diseases (AID)
* Project code: 2041277.
* Awarded $78,250
* Started on 1/6/07
* Finished by 31/5/08

1. CUHK Direct grant 2008

### Project entitled “Measurement of tumor necrosis factor α, leukotriene B4, and interleukin 8 in the exhaled breath condensate in rheumatic disease patients with active disease before and after commencement of immunosuppressants”.

### Awarded $40,000

### Started on 1/3/08

### Finished by 28/2/09

1. CUHK Direct grant 2008-2009 (PI: Dr. Edmund K. Li),

* Project title “Comparison of bone architecture in patients with systemic lupus erythematosus (SLE) with and without vertebral fractures on corticosteroid and healthy controls with high-resolution peripheral quantitated computed tomography (HR-pQCT)”
* Total amount: HK$39,000
* Duration: 22/6/2009-21/6/2010

1. CUHK Direct grant 2009.1.027 (PI: Dr. LS Tam),

* Project title “Function and expression profile of the nucleotide-binding and oligomerization domain (NOD)-2 receptors in systemic lupus erythematosus”
* Total amount: HK$30,000
* Duration: 1/4/2010-31/3/2011

1. CUHK Direct grant Ref No:2041659

Project title “HMGB1: a danger signal molecule of the innate immune response for the immunopathogenesis of systemic lupus erythematosus”

* Total amount: HK$18,000
* Duration: 15/06/2011-14/06/2012

1. CUHK Direct Grant Project code: 2041700

* Project title “Bone quality in men with rheumatoid arthritis: A case-control study using the high-resolution peripheral quantitative computer tomography”
* Total amount: HK$ 25,000
* Duration: 1/4/2012-31/3/2013

1. CUHK Direct Grant Project code: 2012.2.010

|  |  |
| --- | --- |
| * Immunopathological roles of the novel anti-inflammatory cytokine interleukin-35 in patients with systemic lupus erythematous | |
| * Total amount: HK$46,500 |

* Duration: 30/6/2013-29/6/2014

1. CUHK Direct grant 2015 (PI: Dr. Tam Lai Shan)

* Project title: IL-35 in rheumatoid arthritis: exploring its therapeutic potential for the development of a novel targeted biologic therapy. Project code: 2041277.
* Awarded $30000
* Started on 1/6/15
* Finished by 31/5/16

**Non-external competitive grant in the capacity of Co-Investigator**

1. Centre for Emerging Infectious Disease Grant 2005, CUHK-CS007

Project title: Natural history of Cervicovaginal Papillomavirus Infections in immunocompetent and Immunocompromised Chinese Women

#### Grant agency: Research Fund for the Control of Infectious Diseases (RFCID)

* Awarded $60,000
* Year: 2005
* Percentage of contribution: 40%, I am responsible for patient recruitment, management, data analysis and writing up of the manuscript

1. CUHK Direct grant 2007

Project title: Activation of Intracellular Mitogen Activated Protein Kinases in T, B Lymphocytes and Macrophages in Patients with Systemic Lupus Erythematosus

#### Grant agency: CUHK

* Awarded $53,500
* Year: 2007
* Percentage of contribution: 30%, I am responsible for patient recruitment and management

1. CUHK Direct grant 2008

Project title: Comparison of bone architecture in patients with systemic lupus erythematosus (SLE) with and without vertebral fractures on corticosteroid and healthy controls with high-resolution peripheral quantitative computed tomography (HR-pQCT)”

#### Grant agency: CUHK

* Awarded: HK$39,000
* Year: 2009
* External competitive grant: No
* Capacity: Co-Investigator
* Percentage of contribution: 30%, I am responsible for patient recruitment and management

1. CUHK Direct grant 2009.1.025

* Project title “Human papillomavirus infection in patients with systemic lupus erythematosus- predictors for cervical intraepithelial neoplasia”
* Awarded: HK$35,000
* Year: 1/4/2010

1. CUHK Direct grant 2010.1.037 **(PI: Dr. E K Li),**

* Project title “In vivo assessment of bone microarchitecture and bone perfusion in osteoporotic patients with systemic lupus erythematosus”
* Awarded: HK$40,000
* Year: 01/02/2011

1. CUHK Direct grant Ref No:2041659

* Project title “HMGB1: a danger signal molecule of the innate immune response for the immunopathogenesis of systemic lupus erythematosus”
* Awarded: HK$18,000
* Year: 15/06/2011

1. **CUHK Direct grant 2009.1.025 (PI: Dr. E K Li),**

Project title “Human papillomavirus infection in patients with systemic lupus erythematosus- predictors for cervical intraepithelial neoplasia”

* Total amount: HK$35,000
* Duration: 1/4/2010-31/3/2011

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  | | |
|  |  |  |  |  |

INTERNSHIP

Prince of Wales Hospital

The Chinese University of Hong Kong July 1992 - June 1993

POST GRADUATE TRAINING AND WORK EXPERIENCE

### Medical Officer in General Internal Medicine Training

Department of Medicine

Prince of Wales Hospital July 1993- June 1996

Clinical Fellow, Rheumatology Sept 1998- Aug 1999

Centre for Prognostic Studies in Rheumatic Diseases

Toronto Western Hospital

### University of Toronto

### Canada

#### Specialist in Rheumatology Dec 2000- Sept 2006

Department of Medicine

Prince of Wales Hospital

Associate Professor Oct 2006- July 2010

Department of Medicine & Therapeutics

The Chinese University of Hong Kong

PRESENT APPOINTMENT Aug 2010- present

Professor

Department of Medicine & Therapeutics

The Chinese University of Hong Kong

QUALIFICATIONS

#### MB. ChB 1992

MRCP (UK) 1995

FHKCP (Med) 2000

FHKAM 2000

MD (CUHK) 2006

FRCP (Glasg 2008-2018, Lond 2012-, Edin 2012-2018)

LICENSING

Annual Practicing Certificate, Medical Council of Hong Kong

## HONORARY APPOINTMENT

Honorary Clinical Assistant Professor

Department of Medicine

The Chinese University of Hong Kong July 2003 – to Sept 2006

Honorary Associate Consultant Oct-2006 to Feb 2012

New Territories East Cluster

Hospital Authority

Honorary Consultant March 2012 to 2.4.2019

New Territories East Cluster

Hospital Authority

Visiting Professor Jun 2011 to Jun 2013

Shanghai Medical College

Fudan University

China

PROFESSIONAL MEMBERSHIP

1. President of the Hong Kong Society of Rheumatology 2010-2013
2. Fellow of the Royal College of Physicians
3. Fellow of the Hong Kong College of Physicians
4. Fellow of the Hong Kong Academy of Medicine
5. Member of Hong Kong Medical Association
6. Member of the Royal College of Physicians ( UK )
7. Member of the Medical Protection Society Limited

CONTRIBUTION TO TRAINING OF PHYSICIANS

1. Hong Kong College of Physicians
   1. Specialty Board in Rheumatology/ Immunology & Allergy, Hong Kong College of Physicians

Member July 2007 -June 2013

Programme Director July 2013 -June 2015

Chairman July 2015 -June 2019

* 1. Basic Physician Board for New Territories East Cluster

Assistant Program Director July 2007 – June 2011

Program Director (Deputy) July 2011-June 2013

* 1. Member of the scientific committee Dec 2016
  2. Member of the Education and Accreditation committee July 2017 to June 2021

KEY MEMBER

1. Centre of Research and Promotion of Women's Health since Feb 2010

MEMBER OF INTERNATIONAL GROUP

1. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) since Feb 2012
2. Asia Pacific League Against Rheumatism (APLAR)
   1. Chairperson of the international affair subcommittee since Sept 2012
   2. Vice-president Apr 2014 to Sept 2016
   3. Scientific committee member since Oct 2016
   4. Convener of the spondyloarthritis (SpA) special interest group

Oct 2016 to Sept 2018

* 1. Co-convener of the Recommendation guideline committee for SpA

Oct 2016 to Sept 2018

1. Shenzhen Research Institute (SZRI) July 2011- June 2016
2. Member of the American College of Rheumatology (ACR)
   1. International member since Aug 2014
   2. International Task Force subcommittee May 2014 to Mar 2015
   3. Membership Task Force subcommittee Mar 2015 to Apr 2016
3. The Study GrouP for XTrEme-CT in RA (SPECTRA) group
   1. Member since June 2014
   2. Chairperson (Asia) since Nov 2014
4. EULAR Programme Committee member since Mar 2016

Responsible for the programme content of the Annual EULAR Congress responsible for preparations for the congresses 2017 (Madrid), 2018 (Amsterdam) and 2019 (Madrid)

1. Chairperson of the RA Nurse Specialist Education Expert Working Group since Jan 2017
2. Steering Committee Member of the Adaptive Trial Design Special Interest Group since 2017
3. Member of the Asian-Pacific practice guidelines panel on safely use of NSAID since 2018
4. Portable monitoring of biomarkers in chronic immune disease consortium.

HK: CY Tsui (PI, HKUST), Alex Lau (CUHK), Yi-Chun Lu (CUHK), Lai-Shan Tam (CUHK). MIT: Joel Voldman (Co-PI), Yang Shao-Horn. Sponsoring Company: Merck, Jerry Li. we will develop a first prototype system capable of multiplex measurement of 3-5 protein biomarkers in blood or plasma using enhanced electrochemical assays. In the second aim, we will develop a second prototype system with custom circuitry and power systems to enable portable device development, eventually leading to a handheld device akin to a handheld blood glucose meter. Since 2018

1. 廣東省醫學會風濕病學分會擬與香港、澳門風濕病學會共同成立“粵港澳大灣區風濕免疫專業聯盟”。誠邀您代表香港風濕病學會出任專業聯盟的副主席

since March 2019

1. Leader of the APLAR COVID-19 recommendation steering committee since March 2020

CONTRIBUTION TO DEPARTMENT AND FACULTY

1. Radiation safety co-coordinator of the Department of Medicine & Therapeutics 2007-2013
2. Intern coordinator of the Department of Medicine & Therapeutics 2007-2012
3. Member of the Department Service Committee since July 2007
4. Conference & Research Grant Committee of Shaw College, CUHK

Member 2008-2017

Chairman 29/9/2017 to 31/7/2018

1. Work Group on Conference Grant of Shaw College, CUHK

Chairman 1/8/2018 to 31/7/2020

1. Member of the Joint Scientific Committee for the Phase 1 Clinical Trials in Hong Kong, Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR) since oct 2014
2. Member of the Fitness to Practice Committee of the Faculty of Medicine 20/7/2015 to 30/6/2022
3. Mentor, women-focused network, faculty mentoring scheme CUHK until July 31, 2017
4. Mentor, CUHK buddy group since 2016
5. Mentor, GPS student since Sept 2019

ORGANIZING COMMITTEE FOR CONFERENCES

1. Advances in Medicine Conference since 2005
2. Organizer of the CUHK Departmental research day 2007
3. Huaxia Congress on Diagnosis and Management of Rheumatic Diseases in Hong Kong 2007
4. Member of the organizing committee and chairperson for the scientific subcommittee for the Congress of the Asia Pacific League of Associations for Rheumatology (APLAR) 2010 in Hong Kong.
5. International Scientific Committee for the Excellence in Rheumatology Congress 2012 in Madrid, Spain.
6. Autoimmunity Congress Asia 2013 in Hong Kong.
7. **The East Asian Group of Rheumatology (EAGOR 2013 and 2019)** meeting co-ordinator
8. 20th International Bone Densitometry Workshop 2014 in Hong Kong
9. Chairperson, organizing subcommittee, International Conference of Chinese Rheumatologists since 2016
10. Chief organizer, Enhancing Patient Centred Care through Improving Chronic Disease Management for Rheumatoid Arthritis: Collaboration and Exchange Expert Workshop at the Prince of Wales Hospital, Hong Kong, 10-11 May 2016
11. Member of the organizing committee and chairperson for the scientific subcommittee for the Congress of the Asia Pacific League of Associations for Rheumatology (APLAR) since 2014.
12. Member of the organizing committee of the Hong Kong College of Physicians Annual Scientific Meeting since 2017
13. Scientific Committee member, 4th APBMR Meeting & Os Fx Conference, 11-13 May, 2018, Hong Kong
14. Member, scientific planning committee, BMJD Conference that will be held in Bangkok next year, 8-10 November.
15. Abstract reviewer for ACR 2018, 2019, EULAR 2016-2019
16. GRAPPA adjacent symposium to APLAR 2018.
17. 20 January 2019 HK GRAPPA meeting
18. CUHK Psoriatic Arthritis Workshop 29 June 2019
19. GRAPPA adjacent symposium to APLAR 2019.
20. Steering Committee member of a new initiative Pfizer is planning entitled the Immunology Research-Forum in Fall 2020

TEACHING and TRAINING

-Supervisor of MPhil and PhD program at CUHK

-Trainer in Rheumatology

-Medical students at CUHK

-MRCP candidates

-AIM candidates

-Chinese Medicine course at CUHK

- MSc in Sports Medicine and Health Science at CUHK

- MSc in Women’s Health Program at CUHK

- Perspectives in Clinical Sciences (UGB279Z) (General Education course for undergraduates)

-Educational talks to general practitioners, nurses, pharmacists, allied health professionals, Family Planning Association and Advances in Medicine course at CUHK

-Educational talks to general public and rheumatic disease patients

Editorial Board

Editor - Hong Kong Bulletin on Rheumatic Disease 2008-2012

Editor of the departmental brochure published in March 2009.

Member, Rheumatology Jan 2013 –Dec 2017

Associate Editor, International Journal of Rheumatic Diseases Feb 2013- Jan 2016

Member, Latin American Journal of Psoriasis and Psoriatic Arthritis Feb 2013 -

Member, Scientific Reports Aug 2014 – Apr 2017

Member, Rheumatology Practice and Research May 2016 -

Member, Rheumatology, a section of Frontiers in Medicine Sept 2016 –

Member, International Advisory Board, The Lancet Rheumatology Feb 2019

Member, Rheumatology and Immunology Research Dec 2019

Reviewer for Journals

### Seminars in arthritis and rheumatism Apr 2020

### RMD open Apr 2020

### The Journal of Rheumatology 1999, 2006, 2009, 2012, 2013, 2014, 2015, 2019,2020

#### Clinical Drug Investigation 2003

# The Hong Kong Medical Journal 2005

International Journal of Rheumatic Diseases 2005, 2009, 2010, 2013, 2014, 2020

The Scandianvian journal of Rheumatology 2005

Free Radical Biology & Medicine 2006

### Rheumatology (Oxford) 2007, Sept 2013

### Peritoneal Dialysis International Aug, 2008

### Medical Science Monitor Nov, 2008

### BMC Neurology May, 2009

### Arthritis and Rheumatism Aug, 2009, Nov 2017, May 2018

### Nephron Clinical Practice Oct, 2009

### Clinical and Experimental Rheumatology Jan, 2010

Stroke Dec 2010

Journal of the European Academy of Dermatology and Venereology July 2011

Journal of Aging Research July 2011

Arthritis Care & Research July 2011, July and Sept 2012

Journal of Gastroenterology and Hepatology Sept 2011, Feb 2015

BMC Nephrology Feb 2012

Lupus June 2012

Arthritis Research & Therapy July 2012, Oct 2014, Oct 2018

Laboratory Investigation Aug 2012

Journal of the European Academy of Dermatology and Venereology Feb 2013

Annals of Rheumatic Disease Jun 2013, Dec 2013, Jan, May 2014,

May 2015, Jan 2016, June 2016, Sept 2017

JAMA Aug 2013

European Journal of Clinical Investigation Oct 2013

Clinical Rheumatology Jan 2014

Nature Review Rheumatology Jan 2014

# PLos One July 2016

Scientific reports Dec 2016

Heart Oct 2017

# Reviewer for research grants

# Dutch Arthritis Association Feb 2010

# Hong Kong Health and Health Services Research Fund (HHSRF) and the Research Fund for the Control of Infectious Diseases (RFCID).   1 Feb 2011 to 30 Sept 2014

Arthritis Research UK Feb 2012

Research Grant Council Hong Kong Mar 2013

# External Reviewer for assessment of promotion for academic staffs from National University of Singapore May 2013

Food and Healthy Bureau, Government Secretariat of the HKSAR, Grant Review Board member 1 Oct 2014-30 Sept 2020

CUHK Research Committee, Direct grant for research since Jan 2016

National Medical Research Council (NMRC), Ministry of Health, Singapore. July 2017

# PUBLICATIONS

1. Tam LS, Cohen MG, Li EK. Hemiballismus in systemic lupus erythematosus: possible association with antiphospholipid antibodies. *Lupus* 1995; 4: 67-9.
2. Tam LS, Chan TY, Leung, Critchley JA. Warfarin interactions with Chinese traditional medicines: danshen and methylsalicylate medicated oil. *Aust N Z J Med* 1995; 25:258.
3. Chan TY, Chan LY, Tam LS, Critchley JA Neurotoxicity following the ingestion of a Chinese medicinal plant, Alocasia macrorrhiza. *Hum Exp Toxicol* 1995; 14 :727-8.
4. Sung JJ, Tam LS, Ko GT, Lui SF, Cockram CS, Lai KN. Deception and self-harm in the quest for freedom: an audit of Vietnamese boat people admitted to a regional hospital in Hong Kong. *Med J Aust* 1995; 163: 524-6.
5. Chan TY, Tam LS, Chan LY. Stonefish sting: an occupational hazard in Hong Kong. *Ann Trop Med Parasitol* 1996; 90: 675-6.
6. Li EK, Tam LS, Young RP, Ko GT, Li M, Lau EM. Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids. *Br J Rheumatol* 1998; 37: 405-10.
7. Tam LS, Li EK. Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. *Lupus* 1998; 7:495-7.
8. Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, Szeto CC, Lui SF. Long-term treatment of lupus nephritis with cyclosporin A. *QJM* 1998; 91:573-80.
9. Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 Chinese patients. *J Rheumatol* 1999; 26: 1923-9.
10. Tam LS, Li EK, Lam CWK, Tomlinson B. Hydroxychloroquine has no effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. *Lupus* 2000; 9:413-6.
11. Tam LS, Gladman DD, Hallet D, Rahman P,Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. *J Rheumatol* 2000; 27:2142-5.
12. Rahman P, Gladman DD, Urowitz MB, Hallet D, Tam LS. Early damage is a predictor of mortality in SLE. *Lupus* 2001; 10:93-6.
13. Tam LS, Li EK, Benzi IFF, Lam CWK, Arymanayagam M, Chung WY, Tomlinson B. Metabolic abnormalities associated with microalbuminuria in systemic lupus erythematosus. *Rheumatology* 2001; 40:1193-94.
14. Tam LS, Li EK, Szeto CC, Wong SM, Leung CB, Lai FM, Wong KC, Lui SF. Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A. *Lupus* 2001; 10: 827-9.
15. Thomas N, Tam LS, Tomlinson B, Li EK. Accelerated atherosclerosis in patients with systemic lupus erythematosus: A review of the causes and possible preventions. *Hong Kong Med J* 2002; 8: 26-32.
16. Ho CY, Wong CK, Li EK, Tam LS, Lam CWK. Expression of Cyclin B1 and Cyclin-dependent Kinase Inhibitor p21 of Lymphocytes in Patients with Systemic Lupus Erythematosus. *J Rheumatol* 2002, 29: 2537-2544
17. Tam LS, Li EK, Wong SM, Szeto CC. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. *Scand J Rheum* 2002, 31:1-5.
18. Wong CK, Ho CY, Li EK, Tam LS, Lam CWK. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. *Clin Exp Immunol* 2002, 130:345-351.
19. Ho CY, Wong CK, Li EK, Tam LS, Lam CWK. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin, and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. *Rheumatology 2003*, 42:117-122.
20. Chan RW, Tam LS, Li EK, Lai FM, Chow KM, Lai KB, Li PK, Szeto CC. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. *Arthritis Rheum* 2003; 48:1326-31.
21. Tam LS, Fan B, Li EK, Thomas GN, Yim SF, Haines CJ, Tomlinson B. Patients with Systemic lupus erythematosus show increased platelet activation and endothelial dysfunction induced by acute hyperhomocysteinemia*. J Rheumatol* 2003, 30: 1479-84.
22. Ho CY, Wong CK, Li EK, Tam LS, Lam CWK. Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. *Clin Exp Immunol* 2003, 133:132-8.

# Tam LS, Li EK, Lai FM, Chan YK, Szeto CC. Mesangial Lupus Nephritis In Chinese Is Associated With A High Rate Of Transformation To Higher Grade Nephritis. *Lupus* 2003, 12:665-71.

1. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. *J Rheumatol*. 2003;30:1955-9.
2. Chan YK, Li EK, Tam LS, Chow LT, Ng HK. Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. *Scand J Rheumatol*. 2003;32:306-8.
3. Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. *Clin Ther* 2004;26:447-59.
4. Hui D, Wong KT, Antonio GE, Lee N, Wu A, Wong V, Lau W, Wu JCY, Tam LS, et al. Severe Acute Respiratory Syndrome (SARS): Correlation of Clinical Outcome and Radiological Features. *Radiology* 2004, 233:579-585.
5. Tam LS, Li EK, Wong CK, Lam CWK, Szeto CC. Double blind, randomized, placebo controlled pilot study of leflunomide in systemic lupus erythematosus (SLE). *Lupus*, 2004;13:601-4.
6. Chan RW, Lai FM, Li EK, Tam LS, Wong TY, Szeto CY, Li PK, Szeto CC. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. *Arthritis Rheum*. 2004 ;50:2882-90.
7. Tam LS, Chan AYK, Chan PKS, Chang AR, Li EK. Higher prevalence of squamous intraepithelial lesion in systemic lupus erythematosus-association with human papillomavirus infection. *Arthritis Rheum*, 2004, 50:3619-3625.
8. Chan AY, Li EK, Tam LS, Cheng G, Choi PC. Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid. *Rheumatol Int*. 2005 25: 388–390.
9. Tam LS, Li EK, Leung, Griffith JF, Benzie IFF, Lim PL, Whitney B, Lee VWY, Lee KKC, Thomas GN, Tomlinson B. The effects of vitamins C and E on oxidative stress markers and endothelial function in patients with Systemic Lupus Erythematosus: a double-blind, placebo-controlled pilot study. *J Rheumatol*, 2005;32:275-82.
10. Wong CK, Lit LCW, Tam LS, Li EK, Lam CWK. Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. *Rheumatology* 2005, 44: 602-606.
11. Chan RW, Chow KM, Tam LS, Li EK, Wong SM, Li PK, Szeto CC. Can the urine dipstick test reduce the need for microscopy for assessment of SLE disease activity? *J Rheumatol*, 2005;32:828-31.
12. Wong CK, Lit LCW, Tam LS, Li EK and Lam CWK. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology 2005, ;44:989–994.
13. Hui DS, Wong KT, Ko FW, Tam LS, Chan DP, Woo J, Sung JJ. The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. *Chest* 2005;128;2247-2261.
14. Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006;65:209-215.
15. Tam LS, Li EK, Wong CK, Lam CWK, Sezto CC. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open-label trial. Ann Rheum Dis 2006; 65: 417-418.
16. Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC. Imbalance of Th1 / Th2 transcription factors in patients with lupus nephritis. Rheumatology (Oxford). 2006;45:951-7. Epub 2006 Feb 3.
17. Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol Dial Transplant 2006;21 ;1534-40. Epub 2006 Jan 31.
18. Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC. Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis. Nephrolology (Carlton) 2006;11:219-25.
19. Chan RW, Lai FM, Li EK, Tam LS, Chung KY, Chow KM, Li PK, Szeto CC. Urinary mononuclear cell and disease activity of systemic lupus erythematosus. Lupus 2006;15:262-7.
20. Leung YY, Lo KM, Tam LS, Szeto CC, Li EK, Kun EW. Estimation of glomerular filtration rate in patients with systemic lupus erythematosus. Lupus 2006; 15: 276-81.
21. Tam LS, Griffith JF, Yu AB, Li TK, Li EK. Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and Infliximab: clinical and magnetic resonance imaging evaluation. Clin Rheum 2007 Jun; 26(6):941-6.
22. Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC. Expression of T-bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients predicts disease flare. Rheumatology (Oxford) 2007;46:44-8. Epub 2006 Jun 4.
23. Lit LC, Wong CK, Li EK, Tam LS, Lam CW, Lo YM. Elevated gene \_expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2007, 34:89-96. Epub 2006 Nov 15.
24. Bao YX, Wong CK, Li EK, Tam LS, Leung PC, Yin YB, Lam CW.Immunomodulatory effects of Lingzhi and San-Miao-San supplementation on

patients with rheumatoid arthritis. Immunopharmacol Immunotoxicol 2006; 28:1–4.

1. Leung YY, Szeto CC, Tam LS, Lam CWK, Li EK, Yu SW, Kun EW. Urine Protein-to-Creatinine Ratio in an Untimed Urine Collection Is a Reliable Measure of Proteinuria in Lupus Nephritis. Rheumatology 2007;46:649-52.
2. Szeto CC, Tam LS. Maintenance treatment of proliferative lupus nephritis can be discontinued after remission in some patients. Nat Clin Pract Nephrol. 2006;2:672-3.
3. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheum 2007, Sep;26(9):1495-8.
4. Tam LS, Chan KY, Li EK. The impact of illness and variables associated with functional limitations in Chinese patients with Ankylosing Spondylitis. J Rheumatol 2007;34:1032–9.
5. [Leung YY, Tam LS, Kun EW, Li EK.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17244977&query_hl=1&itool=pubmed_docsum) Psoriatic arthritis as a distinct disease entity. J Postgrad Med. 2007;53:63-71.
6. Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Lai KB, Li PK, Szeto CC. Intra-renal cytokine gene expression in lupus nephritis. Ann Rheum Dis 2007; 66:886-92.
7. Li EK, Tam LS, Wong CK, Li, WC, Tomlinson B, Lam CW, Wachtel-Galor S, Bao Y X, Leung PC. Ganoderma lucidum (lingzhi) and Sen Miao San in rheumatoid arthritis: a double blind, randomized, placebo controlled pilot trial. Arthritis Rheum 2007;57:1143-1150
8. Wang G, Lai FM, Tam LS, Li EK, Lai KB, Chow KM, Li PK , Szeto CC. Messenger RNA expression of podocyte associated molecules in the urinary sediment of patients with lupus nephritis. J Rheumatol 2007;34:2358-64.
9. Lun SW, Wong CK, Tam LS, Li EK, Lam CW. Decreased ex vivo production of TNF-alpha and IL-8 by peripheral blood cells of patients with rheumatoid arthritis after infliximab therapy. Int Immunopharmacology 2007;7:1668-77.
10. Tam LS, Szeto CC. Practice Point commentary on Birmingham DJ et al. (2007) Kidney Int 72: 865-870. Nat Clin Pract Nephrol. 2008;4:72-3. Epub 2007 Nov 6
11. Tam LS, Leung PC, Li TK, Zhang L, Li EK. Acupuncture in the treatment of rheumatoid arthritis: a double-blind controlled pilot study. BMC Complement Altern Med 2007; 7:35.
12. Szeto CC, Mok HY, Chow KM, Lee TC, Leung JY, Li EK, Tsui TK, Yu S, Tam LS. Climatic influence on the prevalence of non-cutaneous disease flare in systemic lupus erythematosus in Hong Kong. J Rheumatol 2008; 35:1031-7.
13. Tam LS, Wong A, Mok VCT, Zhu YE, Kwok LW, Li TK, Wong KC, Li EK. The relationship between neuropsychiatric, clinical and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus. J Rheumatol 2008, 35:1038-45.
14. Tam LS, Tomlinson B, Chu TK, Li M, Leung YY, Kwok CL, Li TK, Yu T, Zhu T, Wong KC, Kun EW, Li EK. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls- the role of inflammation. Rheumatology 2008, 47: 718-723.
15. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clinical Immunology 2008; 127:385-93.

# Leung YY, Tam LS, Kun EW, Li EK. Impact of illness and variables associated with functional impairment in Chinese patients with psoriatic arthritis. Clin Exp Rheumatol 2008, Sep-Oct;26(5):820-6.

1. Li EK, Griffith JF, Lee VW, Wang YX, Li TK, Lee KK, Tam LS. Short term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology 2008;47:1358-63.
2. Shang Q, TamLS, Li EK, Yip GW, Yu CM. Increased Arterial Stiffness Correlated With Disease Activity of Systemic Lupus Erythematosus. Lupus 2008; 17:1096-1102.
3. Leung YY, Tam LS, Kun EW, Ho KW, Li EK. Comparison of 4 Functional indexes in Psoriatic Arthritis with axial or peripheral disease subgroups using Rasch analyses. J Rheum 2008;35:1613–21.
4. Tam LS, Shang Q, Li EK; Tomlinson B, Chu T, Li M, Leung YY, Kwok LW, Wong KC, Li TK, Yu T, Zhu YE, Kun EW, Yip G, Yu CM. Subclinical Carotid Atherosclerosis in Patients with Psoriatic Arthritis. Arthritis Rheum 2008; 59:1322–1331.
5. Zhu YL, Tam LS, VW Lee, Hwang WW, Li EK. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology 2008,47:1422-5.
6. Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Wang G, Li PK. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 2008, 47: 1678-1681.
7. Lam FF, Ko IW, Ng ES, Tam LS, Leung PC, Li EK.Analgesic and Anti-arthritic Effects of Lingzhi and San Miao San Supplementation in a Rat Model of Arthritis Induced by Freund’s Complete Adjuvant. J Ethnopharmacology 2008, 120(1):44-50.
8. Leung YY, Tam LS, Lee KW, Leung MH, Kun EW, Li EK. Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis. Rheumatology (Oxford) 2009; 48: 53-56.
9. ZhuTY, Tam LS, Lee VW, Lee KK, Edmund K. Li EK. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford) 2009; 48: 564-568.
10. Wong PTY, Wong CK, Tam LS, Li EK, Chen DP, Lam CWK. Decreased Expression of T Lymphocyte Co-stimulatory Molecule CD26 on Invariant Natural Killer T Cells in Systemic Lupus Erythematosus. Immunological Investigations 2009, 38:350-64.
11. Yip GW, Shang Q, Tam LS, Zhang Q, Li EK, Fung JW, Yu CM. Disease Chronicity and Activity Predicts Subclinical Left Ventricular Systolic Dysfunction in Patients with Systemic Lupus Erythematosus. Heart 2009, 95:980-7.
12. Wang G, Lai FM, Tam LS, Li EK, Kwan BC, Chow KM, Li PK, Szeto CC. Urinary FOXP3 mRNA in patients with lupus nephritis: relation with disease activity and treatment response. Rheumatology (Oxford) 2009;48:755-60.
13. Li EK, Tam LS, Griffith JF, Zhu TY, Li TK, Li M, Wong KC, Chan M, Lam CW, Chu FS, Wong KK, Leung PC, Kwok AK. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol 2009;36 1646-1652.
14. Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK, Leung YY, Wong KC, Szeto CC. [Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?](http://www.ncbi.nlm.nih.gov/pubmed/19478041?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=12) . Rheumatology (Oxford) 2009, 48: 892-898.
15. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009, 15;61(9):1159-67.
16. Tam LS, Leung YY, Li EK. Psoriatic arthritis in Asia. Rheumatology (Oxford) 2009;48: 1473-1477.
17. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Activation profile of intracellular mitogen - activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus. J Clin Immunol 2009, Nov;29(6):738-46.
18. Kwan BC, Tam LS, Lai KB, Lai FM, Li EK, Wang G, Chow KM, Li PK, Szeto CC. The gene expression of type 17 T-helper cell (TH17)-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:1491-1497.
19. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol 2010; 30:45–52
20. Leung YY, Tam LS, Ho KW, Lau RWH, Li TK, Zhu TY, Kun EW, Li EK. Evaluation of the CASPAR criteria for Psoriatic Arthritis in Chinese. Rheumatology (Oxford) 2010 49: 112-115.
21. Wong CK, Wong P, Tam LS, Li EK, Chen DP, Lam CWK.  
    Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2009, Nov;159(1):11-22.
22. Kuan WP, Tam LS, Wong CK, Ko FW, Li TK, Zhu TY, Li EK. CXCL 9 and CXCL 10 as Sensitive Markers of Disease Activity in Patients with Rheumatoid Arthritis. J Rheumatol 2010; 37 257-264
23. Tam LS, Chan PK, HoSC, YuMM, Yim SF, Cheung TH, **Wong MC,** Li EK.Natural History of Cervical Papillomavirus Infection in Systemic Lupus Erythematosus - A Prospective Cohort Study. J Rheumatol 2010;37 330-340
24. Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon E, Ko GT, Baum L, Tam LS, Li EK. ABCG2 Polymorphism is Associated with the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin. Clin Pharmacol Ther 2010;87:558-62.
25. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. The relationship between flare and health-related quality of life of patients with systemic lupus erythematosus. J Rheumatol 2010;37 568-573
26. Zhu TY, Tam LS, YY Leung, LW Kwok, KC Wong, T Yu, EW Kun, Li EK. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 2010;37 1214-1220.
27. Leung YY, Ho KW, Tam LS, Zhu TY, Kun EW, Li EK. Testing Scaling Assumptions, Reliability and Validity of Medical Outcomes Study Short-Form-36 Health Survey in Psoriatic arthritis. Rheumatology 2010; Aug;49(8):1495-501.
28. Kuan WP, Li EK, Tam LS. Lupus organ damage: What is damaged in Asian patients? Lupus 2010, 2010;19(12):1436-41.
29. Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010 2010 Jul;6(7):399-405.
30. Hu M, Lui SS, Mak VW, Chu TT, Lee VW, Poon EW, Tsui TK, Ko GT, Baum L, Tam LS, Li EK, Tomlinson B. [Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients.](http://www.ncbi.nlm.nih.gov/pubmed/20679960) Pharmacogenet Genomics 2010 Oct;20(10):634-7.
31. Tam LS, Leung CC, Ying SK, Lee GK, Yim CW, Leung YY, KunEW, Wong KK, Li EK. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong- the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheum 2010;28(5):679-85.
32. Li EK, Zhu TY, Tam LS, Hung VW, Griffith JF, Li TK, Li M, Wong KC, Leung PC, Kwok AW, Qin L. Bone Microarchitecture Assessment by High-Resolution Peripheral Quantitative Computed Tomography in Patients with Systemic Lupus Erythematosus Taking Corticosteroids. J Rheumatol 2010;37:1473-1479.
33. Wong CK, Chen DP, Tam LS, Li EK, Yin YB, Lam CW. Intracellular mechanisms regulating inflammatory cytokine IL-27 mediated activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2010, 2010, 12(4):R129. Epub 2010 Jul 6.
34. Tam LS, Li EK, Shang Q, Tomlinson B, Li M, Leung YY, Kuan WP, Kwok LW, Li TK, Zhu TY, Kun EW, Yip G, Yu CM. TNF-α blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis-a 2-year pilot study. Ann Rheum Dis 2011;70:705-706
35. Wang G, Tam LS, Li EK, Kwan BC, Chow KM, Luk CC, Li PK, Szeto CC. Serum and urinary cell free miR-146a and miR-155 in patients with systemic lupus erythematosus. J Rheumatol 2010;37 2516-2522
36. Tam LS, Chan P, Ho S, Yu M, Yim SF, Cheung, TH, Wong M, Cheung J, Li EK. Risk Factors For Squamous Intraepithelial Lesions in Systemic Lupus Erythematosus- A Prospective Cohort Study. Arthritis Care Res (Hoboken). 2011; 63:269-76.
37. Mok CC, Tam LS, Chan TH, Lee GK, Li EK, for the Hong Kong Society of Rheumatology. Management of Rheumatoid Arthritis: Consensus Recommendations from the Hong Kong Society of Rheumatology. Clin Rheum 2011;30(3):303-12.
38. Wang G, Tam LS, Li EK, Kwan BC, Chow KM, Luk CC, Li PK, Szeto CC. Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 2011 20(5):493-500. Epub 2011 Mar 3.
39. Li EK, Zhu TY, Hung VY, Kwok AW, Lee VW, Lee KK, Griffith JF, Li M, Wong KC, Leung PC, Qin L and Tam LS. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther 2010;**12**:R198 (22 October 2010)
40. Zhu T, Tam LS, Li EK. Cost of illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2011;63:751-60.
41. Lu JX, Kwan BC, Lai FM, Choi PC, Tam LS, Li EK, Chow KM, Wang G, Li PK, Szeto CC. The gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulo-interstitium of patients with lupus nephritis. Nephrology (Carlton). 2011 May;16(4):426-32.
42. Kwok LW, Tam LS, Zhu TY, Leung YY, Li EK. Predictors of Maternal and Fetal Outcomes in Pregnancies of Patients with Systemic Lupus Erythematosus. Lupus 2011;20:829-36.
43. Zhu T, Tam LS, Li EK. Societal costs of rheumatoid arthritis in Hong Kong: A prevalence-based cost-of-illness study. Rheumatology 2011, 50: 1293-1301.
44. Leung YY, Ho KW, Tam LS, Zhu Y, Kwok LW, Li TK, Kun EW, Li EK.Evaluation of spinal mobility measurements in predicting Axial Psoriatic Arthritis. Clin Rheum 2011, 30(9):1157-62
45. Shang Q, Tam LS, Yip G, Sanderson JE, Zhang Q, Li EK, Yu CM. High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with Psoriatic Arthritis. J Rheumatol 2011, Jul;38(7):1363-70. Epub 2011 Apr 1.
46. Lu JX, Kwan BC, Lai FM, Choi PC, Tam LS, Li EK, Chow KM, Wang G, Li PK, Szeto CC. The gene expression of NGAL and TLR9 in glomerulus and tubulo-interstitium of patients with lupus nephritis. Adv Bioscience Biotechnology 2011**; 2: 33-39**
47. Tam LS, LiEK, ShangQ, TomlinsonB, LeeVW, LeeKK, LiM, KuanWP, LiTK, TseungL, YipGWK, FreedmanB, Yu CM. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis - a randomized controlled pilot trial. Scand J Rheumatol 2011;40:411-21
48. Leung YY, Tam LS, Li EK. [The perspective on psoriatic arthritis in Asia.](http://www.ncbi.nlm.nih.gov/pubmed/21553000) Curr Rheumatol Rep. 2011;13(4):369-75.
49. Chen DP, Wong CK, Leung PC, Fung KP, Lau BS, Lau CP, Li EK, Tam LS, Lam CWK. Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor-α-activated human fibroblast-like synoviocytes in rheumatoid arthritis. Journal of Ethnopharmacology 2011, 137(1):457-68.
50. Zhu T, Tam LS, Li EK. Labour and non-labour market productivity in Chinese patients with systemic lupus erythematosus. Rheumatology 2012:51:284-92
51. Lu JX, Tam LS, Lai FM, Kwan BC, Choi PC, Li EK, Chow KM, Li PK, Szeto CC. Repeat renal biopsy in lupus nephritis: a change in histological pattern is common. Am J Nephrol 2011 Jul 23;34(3):220-225.
52. Yu SL, Wong CK, Wong PTY, Chen DP, Szeto CC, Li EK, Tam LS.Down-regulated NOD2 by Immunosuppressants in Peripheral Blood Cells in Patients with SLE Reduces the Muramyl Dipeptide-Induced IL-10 Production. PLoS ONE. 2011; 6(8): e23855.
53. Chen DP, Wong CK, Tam LS, Li EK, Lam CW. Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis. Cell Mol Immunol 2011, 8(6):469-78.
54. Leung YY, Zhu TY, Tam LS, Kun EW, Li EK. Minimal Important Difference and Responsiveness to Change of the SF-36 in Patients with Psoriatic Arthritis Receiving Tumor Necrosis Factor-α Blockers. J Rheumatol 2011; 38; 2077-2079.
55. Wang G, Tam LS, Kwan BC, Li EK, Chow KM, Luk CC, Li PK, Szeto CC. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol 2012: 31:435-40.
56. Yu SL, Kuan WP, Wong CK, Li EK, Tam LS. Immunopathological Roles of Cytokines, Chemokines, Signaling Molecules and Pattern-recognition Receptors in Systemic Lupus Erythematosus. Clinical and Developmental Immunology Volume 2012: 2012:715190.
57. Szeto CC, Tam LS, Kwan BC, Lai KB, Wang G, Li EK, Chow KM, Lai FM, Li PK. Monitoring of urinary messenger RNA levels for the prediction of flare in systemic lupus erythematosus. Clinica Chimica Acta 2012, 18;413(3-4):448-55.
58. Lu JX, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Wang G, Li PK, Szeto CC. Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. Nephrology (Carlton) 2012; 17:346-51.
59. Zhu TY, Tam LS, Li EK. [The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects.](http://www.ncbi.nlm.nih.gov/pubmed/22280197) Expert Rev Pharmacoecon Outcomes Res. 2012;12:53-69.
60. Leung YY, Ho KW, Zhu TY, Tam LS, Kun EW, Li EK. Construct validity of the modified numeric rating scale of patient global assessment in psoriatic arthritis. J Rheumatol. 2012;39 844-848.
61. Yu SL, Chan PK, Wong CK, Szeto CC, Ho SC, So K, Yu MM, Yim SF, Cheung TH, Wong MC, Cheung JL, Yeung AC, Li EK, Tam LS. Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in Systemic Lupus Erythematosus. Arthritis Res Ther 2012:18;14(2):R80
62. Shang Q, Yip GW, Tam LS, Zhang Q, Sanderson JE, Lam YY, Li CM, Wang T, Li EK, Yu CM. SLICC/ACR damage Index Independently Associated with Left Ventricular Diastolic Dysfunction in Patients with Systemic Lupus Erythematosus. Lupus 2012, 21(10):1057-62.
63. Hu M, Lui SS, Tam LS, Li EK, Tomlinson B. [The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.](http://www.ncbi.nlm.nih.gov/pubmed/22534644) J Lipid Res. 2012 53: 1384–1389.
64. Wang YX, Griffith JF, Deng M, Li TK, Tam LS, Lee VW, Lee KK, Li EK. [Vertebral body corner oedema vs gadolinium enhancement as biomarkers of active spinal inflammation in ankylosing spondylitis.](http://www.ncbi.nlm.nih.gov/pubmed/22595499) Br J Radiol. 2012;85(1017):e702-8
65. Zhu TY, Li EK, and Tam LS. Cardiovascular Risk in Patients with Psoriatic Arthritis. *Int J Rheumatol*, 2012;2012:714321.
66. Guan J, Wang G, Tam LS, Kwan BC, Li EK, Chow KM, Li PK, Szeto CC. Urinary sediment ICAM-1 level in lupus nephritis. Lupus 2012, 21:1190-5.
67. Shang Q, Tam LS, Sanderson JE, Sun JP, Li EK, Yu CM. Increase in Ventricular-arterial Stiffness in Patients with Psoriatic Arthritis. Rheumatology 2012, 51: 2215-2223.
68. Tang XL,Zhu TY, Hung VY, QinL, WongCK, KunEW, TamLS, Li EK. Increased Organ Damage Associated With Deterioration in Volumetric Bone Density and Bone Microarchitecture in Patients with Systemic Lupus Erythematosus on Long-term Glucocorticoid. J Rheum 2012; 39: 1955-1963.
69. Lu JX, Szeto CC, Tam LS, Lai FM, Li EK, Chow KM, Li PK, Kwan BC. Relation between intra-renal gene expression and the histological class of lupus nephritis; a study on repeat renal biopsy. J Rheumatol 2012, 39:1942-7.
70. TamLS, ShangQ, LiEK, Wong S, Li RJ, LeeKL, LeungYY, YingKY, YimCW, Emily W Kun,LeungMH, LiM, LiTK, ZhuTY, ChuiRK, TseungL, YuSL, KuanWP, YuCM. Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis - a prospective study. Semin Arthritis Rheum 2013;42:333-45.
71. Tam LS, Shang Q, Li EK, Wang S, LiRJ, Lee KL, LeungYY, YingKY, Yim CW, KunEW, LeungMH, LiM, LiTK, ZhuTY, Chui RK, TseungL, YuSL, KuanWP, Yu CM. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis – a randomized trial. J Rheumatol 2012; 39:2267-2275.
72. Zhu TY, Griffith JF, Qin L, Hung VWY, Fong TN, Kwok AW, Leung PC, Li EK, Tam LS. Bone density and microarchitecture: Relationship between hand,  
    peripheral and axial skeletal sites assessed by HR-pQCT and DXA in  
    rheumatoid arthritis. Calcif. Tissue Int. 2012; 91:343-355.
73. Tang XL,Zhu TY, QinL, Kwok AW, Hung VY, KunEW, Griffith JF, Leung PC, Li EK, TamLS. Alterations of Bone Geometry, Density, Microarchitecture and Biomechanical Properties in Systemic Lupus Erythematosus on Long-Term Glucocorticoid: A Case-Control Study Using HR-pQCT. Osteoporos Int 2013; 24:1817–1826.
74. Zhu TY, Griffith JF, Qin L, Hung VW, Fong TN, Au SK, Tang XL, Kwok AW, Leung PC, Li EK, Tam LS. Structure and strength of the distal radius in female  
    patients with rheumatoid arthritis: A case-control study. J Bon Miner Res  
    2013;28:794-806.
75. Touma Z, Gladman DD, MacKinnon A, Carette S, Abu-Shakra M, Askanase A, Nived O, Hanly JG, Landolt-Marticorena C, Tam LS, Sergio Toloza S, Nikpour M, Riddell C, Steiman A, Eder L, Haddad A, Barber C, Urowitz MB. Development and Assessment of Users' Satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website. J Rheumatol 2013;40:34-39.
76. Wong PC, Leung YY, Li EK, Tam LS. Measuring Disease Activity in Psoriatic Arthritis. Int J Rheum 2012;2012:839425.
77. Szeto CC, Kwan BC, Tam LS. Urinary mRNA in systemic lupus erythematosus. Adv Clin Chem 2013, ;62:197-219.
78. To KW, Gomez-Reino JJ, Yoo DH, Tam LS. Tumor Necrosis Factor Antagonist and Tuberculosis in Patients with Rheumatoid Arthritis: An Asian Perspective. Respirology 2013, ;18:765-73.
79. Tang XL,Griffith JF,Li EK, QinL, Hung VY, Zhu TY, Kwok AW, KunEW, Leung PC, TamLS. SLE disease per se contributes to deterioration in bone mineral density, microstructure and bone strength. Lupus 2013;22:1162-8.
80. Yu SL, Wong CK, Tam LS. [The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus.](http://www.ncbi.nlm.nih.gov/pubmed/23971752) Expert Rev Clin Immunol. 2013;9:739-49.
81. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators. [Macitentan and morbidity and mortality in pulmonary arterial hypertension.](http://www.ncbi.nlm.nih.gov/pubmed/23984728) N Engl J Med. 2013 Aug 29;369(9):809-18.
82. Mok CC, Tam LS, Leung MH, Ying KY, To CH, Lee KL, Ho LY, Yip ML, Tsui HS, Chan TH, Lee KW, Li EK; Hong Kong Society of Rheumatology. [Referral strategy for early recognition of axial spondyloarthritis: consensus recommendations from the Hong Kong Society of Rheumatology.](http://www.ncbi.nlm.nih.gov/pubmed/24164836) Int J Rheum Dis. 2013;16:500-8.

# Mok CC, Chan KY, Lee KL, Tam LS, Lee KW; Hong Kong Society of Rheumatology. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. Int J Rheum Dis. 2014 Dec;17 Suppl 3:1-8. doi: 10.1111/1756-185X.12264. Epub 2013 Dec 30

# Tam LS, Kitas GD, González-Gay MA. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology 2014;53:1108-19.

1. Shang Q, Tam LS, SandersonJE, LeeAP, Li EK, Yu CM. Impaired Left Ventricular Apical Rotation is Associated with Disease Activity of Psoriatic Arthritis. J Rheumatol 2014;41:706-13
2. Tam LS, ShangQ, KunEW, LeeKL, YipML, LiM, LiTK, ZhuTY, PuiMO, Li EK, YuCM. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis – a randomized, placebo- controlled pilot trial. Rheumatology 2014;53:1065-1074
3. Szeto CC, Kwan BC, Tam LS. Chapter Five – Urinary mRNA in Systemic Lupus Erythematosus. [Advances in Clinical Chemistry](http://www.sciencedirect.com/science/bookseries/00652423) 2013; 62:197-219.
4. Zhu TY, Griffith JF, Au SK; Tang XL, Kwok AW, Leung PC, Li EK, Tam LS. Bone mineral density change in systemic lupus erythematosus: A five-year follow-up study. J Rheumatol 2014;41:1990-7
5. Zhu TY, Griffith JF, Au SK; Tang XL, Kwok AW, Leung PC, Li EK, Tam LS. Incidence of and risk factors for non-vertebral and vertebral fracture in female Chinese patients with systemic lupus erythematosus: A five-year cohort study. Lupus 2014, 18;23:854-861
6. Zhu TY, Griffith, JF, Qin L, Hung VW, Fong TN, Au SK, Li M, Lam YY, Wong CK, Kwok AW, Leung PC, Li EK, Tam LS. Alterations of bone density, microstructure and strength of the distal radius in male patients with rheumatoid arthritis: A case-control study with HR-pQCT. J Bone Miner Res 2014; 29:2118-29.
7. Zhu TY, Griffith, JF, Qin L, Hung VW, Fong TN, Au SK, Kwok AW, Leung PC, Li EK, Tam LS. Density, Structure and Strength of the Distal Radius in Patients with Psoriatic Arthritis: The Role of Inflammation and Cardiovascular Risk Factors. Osteoporosis Int 2015, 26;261-272.
8. Rainer TH, Cheng CH, Graham CA, Janssens HJ, Man CY, Tam LS, Choi YF, Yau WH, Lee KH. [Oral prednisolone in the treatment of acute gout: a pragmatic, multi-centre, double-blind, randomized, equivalence trial.](http://www.ncbi.nlm.nih.gov/pubmed/25125529) Emerg Med J. 2014;31:781. doi: 10.1136/emermed-2014-204221.10.
9. Leung YY, Ho KW, Li EK, Li M, Kwok LW, Wong PC, Li TK, Zhu TY, Kun EW, Tam LS. [Predictors of functional deterioration in Chinese patients with Psoriatic arthritis: a longitudinal study.](http://www.ncbi.nlm.nih.gov/pubmed/25160684) BMC Musculoskelet Disord. 2014 Aug 26;15(1):284.
10. Leung YY, Kwan J, Chan P, Poon PK, Leung C, Tam LS, Li EK, Kwok A. A pilot evaluation of Arthritis Self-Management Program by lay leaders in patients with chronic inflammatory arthritis in Hong Kong. Clinical Rheumatology 2014 Oct 8. [Epub ahead of print].
11. Yu SL,Wong CK, Szeto CC, Li EK**,** Cai Z, Tam LS. Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis. Lupus 2015; 24: 675–686.
12. ChanRW, JiangP, PengX, TamLS, LiaoGJ, Li EK, WongPC, SunH, ChanAK, ChiuRW, LoDY. Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):E5302-11. doi: 10.1073/pnas.1421126111. Epub 2014 Nov 26.
13. Zhu TY, Griffith JF, Qin L, Hung VWY, Fong TN, Au SK, Tang XL, Kun EW, Kwok AW, Leung PC, Li EK, Tam LS. Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: A two-year case-control study. Osteoporos Int 2015, 26(6):1759-71
14. Shen J, Shang Q, Wong CK, Li EK, Wang S, Li RJ, PhD, Lee KL, Leung YY, Ying KY, Yim CW, Kun EW, Leung MH, Li M, Li TK, Zhu TY, Yu SL, Kuan WP, Yu CM, MD, Lai-Shan Tam LS. IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: a prospective study, Semin Arthritis Rheum, 2015,45(1):18-27.
15. Shen J, Shang Q, Li EK, Leung YY, Kun EW, Kwok LW, Li M, Li TK, Zhu TY, Yu CM and Tam LS. Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Res Ther 2015: **17**:75.
16. Griffith JF, Wang D, Shi L, Yeung DK , LeeR, Tam LS. Computer-aided assessment of spinal inflammation on MR in spondyloarthritis. Arthritis Rheumatol 2015; 67: 1789–1797.
17. Lee RK, Griffith JF, Wang DF, Shi L, Yeung DK, Li EK, Tam LS. [Dynamic contrast-enhanced imaging of the wrist in rheumatoid arthritis: dedicated low-field (0.25-T) versus high-field (3.0-T) MRI.](http://www.ncbi.nlm.nih.gov/pubmed/25715838) Skeletal Radiol. 2015;44(8):1095-101.
18. Luk CC, Tam LS, Kwan BC, Wong PC, Ma TK, Chow KM, Lai FM, Li PK, Szeto CC. Intra-Renal and urinary Th9 and Th22 cytokine gene expression in lupus nephritis. J Rheumatol 2015 ; 42:1150-1155
19. Cai Z, Wong CK, Dong J, Chu M, Jiao D, Kam N, Lam C, Tam LS. Remission of systemic lupus erythematosus disease activity with regulatory cytokine IL-35 in MRL/lpr mice. Clin Exp Immunol 2015;181:253-266.
20. Cai Z, Wong CK, Kam NW, Dong J, Jiao D, Chu M, Lam CWK, Tam LS. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus. Lupus 2015 Oct;24(12):1257-66.
21. Shen JY, Shang Q, Tam LS. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Translational Research 2016 Jan;167(1):138-51.
22. Lao L, Hochberg M, Lee DY, Gilpin AM, Fong HH, Langenberg P, Chen K, Li EK, Tam LS, Berman B. Huo-Luo-Xiao-Ling (HLXL)-Dan, a Traditional Chinese Medicine, for Patients with Osteoarthritis of the Knee: A Multi-site, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial. Osteoarthr Cartilage 2015 Dec;23(12):2102-8. doi: 10.1016/j.joca.2015.06.007. Epub 2015 Jun 20.
23. Kam KW, Tam LS, Tam MK, Young AL. [Infliximab in the Treatment of Refractory Ocular Inflammatory Diseases.](http://www.ncbi.nlm.nih.gov/pubmed/26068609) Asia Pac J Ophthalmol (Phila). 2015 Jan-Feb;4(1):19-24. doi: 10.1097/APO.0000000000000036.
24. Kam KW, Young AL, Tam LS, Tam PM. [Authors' Reply to "Infliximab in the Treatment of Refractory Ocular Inflammatory Diseases".](http://www.ncbi.nlm.nih.gov/pubmed/26065508) Asia Pac J Ophthalmol (Phila). 2015 May-Jun;4(3):184. doi: 10.1097/APO.0000000000000124.
25. Cai Z, Wong CK, Dong J, Jiao D, Chu M, Leung PC, Lau CB, Lau CP, Tam LS, Lam CWK. Anti-inflammatory activities of Lingzhi and San Miao San supplementation in MRL/lpr mice: potential traditional Chinese medicine for the treatment of systemic lupus erythematosus. Chin Med 2016; 11:23.
26. Chu M, Wong CK, Cai Z, Dong J, Jiao D, Kam NW, Lam CW, Tam LS. Elevated Expression and Pro-inflammatory Activity of IL-36 in Patients with Systemic Lupus Erythematosus. Molecules 2015 Oct 27;20(10):19588-604.
27. Rainer TH, Cheng CH, Janssens HJ, Man CY, Tam LS, Choi YF, Yau WH, Lee KH, Graham CA. Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multi-centre, Double-Blind, Randomized Trial. Ann Int Med 2016;164(7):464-471.
28. Wong SH, Gao Q, Tsoi KK, Wu WK, Tam LS, Lee N, Chan FK, Wu JC, Sung JJ, Ng SC. Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax 2016 Jan;71(1):64-72.
29. Shen J, Shang Q, Wong CK, Li EK, Kun EW, Cheng IT, Li M, Li TK, Zhu TY, Yu CM, Qin L, Tam LS. Carotid plaque and bone density and microarchitecture in psoriatic arthritis: the correlation with soluble ST2. Sci Rep 2016, 24;6:32116..
30. Tam LS. [The Role of High-resolution Peripheral Quantitative Computed tomography as a Biomarker for Joint Damage in Inflammatory Arthritis.](https://www.ncbi.nlm.nih.gov/pubmed/27698105) J Rheumatol. 2016; 43: 1911-1913.
31. Chu M, Tam LS, Zhu J, Jiao D, Liu DH, Cai Z, Dong J, Lam CW, Wong CK. In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice Immunobiology 2017 Mar;222(3):483-493
32. Yue J, Griffith J, Fan X, Lin S, Wang D, Shen J, Wong P, Li EK, Li M, Li T, Zhu TY, Hung VW, Qin L, Tam LS. Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study. Arthritis Care and Research 2017;69(8):1156-1163
33. Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. GEO-RA Group. Clin Rheumatol. 2017;36(3):485-497.
34. Shen J, Wong KT, Cheng IT, Shang Q, PhD, Li EK, Wong P, Kun EW, Law MY, Yip R, Yim I, Ying S, Li M, Li TK, Wong CK, Zhu TY, PhD, Lee JJ, Chang M, Lee AP, Tam LS. Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Ann Rheum Dis 2017 76(7):1237-1244
35. Shang Q, Li H, Tam LS, Wong CP, Sanderson JE, Yu CM, Tomlinson B. [Inflammatory Burden Is Related to an Early Reduction of LV Functional Reserve in Psoriatic Arthritis.](https://www.ncbi.nlm.nih.gov/pubmed/28528149) JACC Cardiovasc Imaging. 2018;11:369-370.
36. Kam NW, Liu D, Cai Z, Mak Q, Wong CK, Chiu KH, Wong KY, Tsang WL, Tam LS. Synoviocytes-derived interleukin-35 potentiates B cells response in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 2018;45:563-573.
37. Shen J, Lam SH, Shang Q, Wong CK, Li EK, Wong P, Kun EW, Cheng IT, Li M, Li TK, Zhu TY, Lee JJ, Chang M, Lee AP, Tam LS. Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis. J Rheumatol 2018;45:218-226.
38. Wu D, Yue J, Tam LS. Efficacy and safety of biologics targeting IL-6, IL-12/23 and IL-17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology (Oxford); 2018;57:563-571.
39. Tam LH, Shang Q, Li EK, Wong PC, Kwok KY, Kun EW, Yim IC, Lee VK, Yip RM, Pang SH, Lao VW, Mak QW, Cheng IT, Lau XS, Li TK, Zhu TY,Lee AP, Tam LS. Effect of treat-to-target strategies aiming at remission on arterial stiffness in early rheumatoid arthritis - a randomized controlled study. J Rheum 2018, 45:1229-1239 doi:10.3899/jrheum.171128
40. Teixeira V, Tam LS**.** Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. Front Med (Lausanne). 2018 Jan 29;4:262. doi: 10.3389/fmed.2017.00262. eCollection 2017. Review

# Huang D, Cheng YY, Chan PH, Hai J, Yiu KH, Tse HF, Wong KL, Fan K, Li YW, Ng WL, Yim CW, Wong CHJ, Tam LS, Wong PC, Wong CY, Ho CH, Leung AM, Mok CC, Lam H, Lau CS, Cheung T, Ho C, Law SW, Chan EW, Yin LX, Yue WS, Mok TM, Evora MA, Siu CW. Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study. ERJ Open Research 2018 4: 00135-2017; DOI: 10.1183/23120541.00135-2017.

1. Yue J, Griffith JF, Xu J, Xiao F, Shi L, Wang D, Wong PC, Li EK, Li M, Li TK, Mak WY, Zhu TY, Hung VW, Qin L, Tam LS. Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: an HR-pQCT study. Semin Art Rheum 2018 48(3):374-383
2. **Baeten D,** Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Bchir MB, Padula SJ. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding Phase 2 study. Ann Rheum Dis, 2018;**0**:1–8. doi:10.1136/annrheumdis-2018-213328.
3. Yu J, Wu D, Tam LS. The role of imaging in early diagnosis and prevention of joint damage in inflammatory arthritis. Expert Rev Clin Immunol. 2018, May 13. doi: 10.1080/1744666X.2018.1476849. [Epub ahead of print].
4. Lee CK, Wong SH, Lui G, Tang W, Tam LS, Ip M, Hung E, Chen M, Wu JC, Ng SC.

[A prospective study to monitor for tuberculosis during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune mediated inflammatory diseases.](https://www.ncbi.nlm.nih.gov/pubmed/29757355) J Crohns Colitis. 2018 May 11. doi: 10.1093/ecco-jcc/jjy057. [Epub ahead of print]

1. ShenJ, GriffithJF, ZhuTY, TangP, KunEW, LeeVK, Yip RM, Kwok KY, Ying SK, Ho CT, LauSL, Pui MO, Li TK, Lau EY, Lee JJ, Qin L, Tam LS. Bone mass, microstructure and strength can discriminate vertebral fracture in patients on long-term steroid treatment. J Clin Endocrinol Metab 2018, Jul 2. doi: 10.1210/jc.2018-00490. [Epub ahead of print].
2. Cheng IT, ShangQ, Li EK, Wong PC, KunEW, Law MY, YipRM, FRCP, YimIC, Lai BT, FRCP, YingSK, Kwok KY, FHKAM, LiM, PhD, Li TK, Zhu TY, LeeJJ, ChangMM, SzetoCC, MD, Yan BP, Lee AP, Tam LS. Can achieving Minimal Disease Activity prevent progression of subclinical atherosclerosis and arterial stiffness? A prospective cohort study in Psoriatic Arthritis. Arthritis Rheumatol 2019;71:271-280
3. [Lam SH](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lam%20SH%5BAuthor%5D&cauthor=true&cauthor_uid=30173182), [Shen J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Shen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30173182), [Tam LS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tam%20LS%5BAuthor%5D&cauthor=true&cauthor_uid=30173182). Dr. Tam, *et al,* reply. [J Rheumatol.](https://www.ncbi.nlm.nih.gov/pubmed/30173182) 2018;45:1330-1332.
4. Wong SPY, Mok CC, Lau CS, Yip ML, Tam LS, Ying KY, Ng WL, Ng KH, Leung MH, Lee TY, To CH, Lee KL, Wan MC, Yu KL, Wong PCH, Sung CK, Lee KF, Kun EWL; Hong Kong Takayasu’s arteritis study group.[Clinical presentation, treatment and outcome of Takayasu's arteritis in southern Chinese: a multicenter retrospective study.](https://www.ncbi.nlm.nih.gov/pubmed/30182290) Rheumatol Int. 2018;38:2263-2270
5. Wu D, Yue J, Tam LS. Comment on: Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis: reply. Rheumatology (Oxford) 2018;57(11):2062.
6. [Belizna C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Belizna%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Pregnolato F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pregnolato%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Abad S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Abad%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Alijotas-Reig J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Alijotas-Reig%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Amital H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Amital%20H%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Amoura Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Amoura%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Andreoli L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Andreoli%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Andres E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Andres%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Aouba A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Aouba%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Bilgen SA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bilgen%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Arnaud L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Arnaud%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Bienvenu B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bienvenu%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Bitsadze V](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bitsadze%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Blanco P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Blanco%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Blank M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Blank%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Borghi MO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Borghi%20MO%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Caligaro A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Caligaro%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Candrea E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Candrea%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Canti V](https://www.ncbi.nlm.nih.gov/pubmed/?term=Canti%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Chiche L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Chiche%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Chretien JM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Chretien%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Tervaert JWC](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tervaert%20JWC%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Damian L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Damian%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Delross T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Delross%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Dernis E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dernis%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Devreese K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Devreese%20K%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Djokovic A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Djokovic%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Esteve-Valverde E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Esteve-Valverde%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Favaro M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Favaro%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Fassot C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Fassot%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Ferer-Oliveras R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ferer-Oliveras%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Godon A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Godon%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Hamidou M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hamidou%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Hasan M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hasan%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Henrion D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Henrion%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Imbert B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Imbert%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Jeandel PY](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jeandel%20PY%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Jeannin P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jeannin%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Jego P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jego%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Jourde-Chiche N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jourde-Chiche%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Khizroeva J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Khizroeva%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Lambotte O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lambotte%20O%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Landron C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Landron%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Latino JO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Latino%20JO%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Lazaro E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lazaro%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [de Leeuw K](https://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Leeuw%20K%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Le Gallou T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Le%20Gallou%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Levent K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Levent%20K%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Liimper M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Liimper%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Loufrani L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Loufrani%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Lubin R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lubin%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Magy-Bertrand N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Magy-Bertrand%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Mahe G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mahe%20G%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Makatsariya A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Makatsariya%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Martin T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Muchardt C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Muchardt%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Nagy G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nagy%20G%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Omarjee L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Omarjee%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Van Paasen P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Van%20Paasen%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Pernod G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pernod%20G%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Perrinet F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Perrinet%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [da Rosa GP](https://www.ncbi.nlm.nih.gov/pubmed/?term=da%20Rosa%20GP%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Pistorius MA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pistorius%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Ruffati A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ruffati%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Said F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Said%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Saulnier P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Saulnier%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Sene D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sene%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Sentilhes L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sentilhes%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Shovman O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Shovman%20O%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Sibilia J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sibilia%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Sinescu C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sinescu%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Stanisavljevic N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Stanisavljevic%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Stojanovitch L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Stojanovitch%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Tam LS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tam%20LS%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Tincani A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tincani%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Tollis F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tollis%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Udry S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Udry%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Ungeheuer MN](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ungeheuer%20MN%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Versini M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Versini%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Cervera R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cervera%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30316994), [Meroni PL](https://www.ncbi.nlm.nih.gov/pubmed/?term=Meroni%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=30316994). HIBISCUS: HYDROXYCHLOROQUINE FOR THE SECONDARY PREVENTION OF THROMBOTIC AND OBSTETRICAL EVENTS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME. [Autoimmun Rev.](https://www.ncbi.nlm.nih.gov/pubmed/30316994) 2018 Oct 11. pii: S1568-9972(18)30229-5. doi: 10.1016/j.autrev.2018.05.012. [Epub ahead of print]
7. Chi WK, Tse G, Choi P, Kam KKH, Tam L, Lee APW, Tam LS. Spondyloarthritis-related autoimmune aortitis complicated by severe aortic regurgitation: The importance of multimodality imaging approach. Circ Cardiovasc Imaging; 2019 Dec;12(1):e008341. doi: 10.1161/CIRCIMAGING.118.008341..
8. Pickles T, Christensen R, TamLS, SimonLS, ChoyEH. Adaptive Trial Designs in Rheumatology: Report from an OMERACT Special Interest Group. J Rheum 2019 46:1406-1408
9. Wang X, Wong SH, Wang XS, Tang W, Liu CQ, Niamul G, Wu B, Tam LS, Wu JCY, Chan FKL, Sung JJY, Ng SC. [Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region.](https://www.ncbi.nlm.nih.gov/pubmed/30561745) Rheumatology (Oxford). 2019;58:803-810.
10. Xiao F, Griffith JF, Hilkens AL, Leung JCS, Yue J, Lee RKL, Yeung DKW, Tam LS. ERAMRS: A New MR Scoring System for Early Rheumatoid Arthritis of the Wrist. European Radiology 2019;29:5646-5654
11. Chan BCL, Lam CWK, Tam LS, Wong CK. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. Frontiers in Immunology, 2019,  Mar 4;10:364. doi: 10.3389/fimmu.2019.00364. eCollection 2019. Review.
12. Tam LS, Wei JC‐C, Aggarwal A, et al. 2018 APLAR axial spondyloarthritis treatment recommendations. *Int J Rheum Dis*. 2019; 22:340-356.
13. Chan BCL, Lam CWK, Tam LS, Wong CK. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. Front. Immunol., 04 March 2019 | <https://doi.org/10.3389/fimmu.2019.00364>
14. Tsoi C, Griffith JF, Lee RKL, Wong PCH, Tam LS. [Imaging of sacroiliitis: Current status, limitations and pitfalls.](https://www.ncbi.nlm.nih.gov/pubmed/30976556)Quant Imaging Med Surg. 2019;9:318-335.
15. Tam LS, Lau CS.  [APLAR Axial Spondyloarthritis Recommendations Working Group](https://www.ncbi.nlm.nih.gov/pubmed/?term=APLAR%20Axial%20Spondyloarthritis%20Recommendations%20Working%20Group%5BCorporate%20Author%5D). Authors reply to Comment on Axial SpA recommendations. *Int J Rheum Dis*. 2019;22:1346–1347.
16. YueJ, Lau TC, Griffith JF, Xu J, XiaoF, Shi L, WangD, WongPC, LiEK, Tam LP, Li M, LiTK, MakWY, HungV, QinL, Tam LS. Circulating miR-99b-5p as a novel predictor of erosion progression on HR-pQCT in early rheumatoid arthritis: a prospective cohort study. Int J Rheum Dis 2019;22:1724-1733.
17. [Pickles T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pickles%20T%5BAuthor%5D&cauthor=true&cauthor_uid=31431982), [Christensen R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Christensen%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31431982), [Tam LS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tam%20LS%5BAuthor%5D&cauthor=true&cauthor_uid=31431982), [Simon LS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Simon%20LS%5BAuthor%5D&cauthor=true&cauthor_uid=31431982), [Choy EH](https://www.ncbi.nlm.nih.gov/pubmed/?term=Choy%20EH%5BAuthor%5D&cauthor=true&cauthor_uid=31431982). Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. [Rheumatol Adv Pract.](https://www.ncbi.nlm.nih.gov/pubmed/31431982) 2018 Oct 17;2(2):rky045. doi: 10.1093/rap/rky045. eCollection 2018.
18. Wu D; Griffith JF; Lam SH; Wong P; Shi L; Li EK; Cheng IT; Li TK; Hung VW; Qin L; Tam LS. Progressive structural bone changes and their relationship to treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study. Arthritis Research & Therapy 2019, 21:265.
19. Ju C, Lai RWC, Li KHC, Hung JKF, Lai JCL, Ho J, Liu Y, Tsoi MF, Liu T, Cheung BMY, Wong ICK, Tam LS, Tse G.[Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.](https://www.ncbi.nlm.nih.gov/pubmed/31873735) Rheumatology (Oxford). 2019 Dec 24. pii: kez576. doi: 10.1093/rheumatology/kez576. [Epub ahead of print]
20. Szeto CC , Sugano K, Wang JG, Fujimoto K, Whittle SL, Modi G, Chen CH, Park JB, Tam LS, Vareesangthip K, Tsoi K, Chan KL. Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy in Patients with Hypertension, Cardiovascular, Renal, or Gastrointestinal Comorbidities: Joint APAGE / APLAR / APSDE / APSH / APSN / PoA Recommendations. Gut 2020 69(4):617-629
21. Cheng IT, LiEK, WongPC, LawMY, YimIC, Lai BT, Ying SK, Kwok KY, LiM, LiTK, LeeJJ, SzetoCC, YanBP, Lee AP, Tam LS. Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis- which target should we choose? Rheumatology 2020, Feb 22. pii: keaa025. doi: 10.1093/rheumatology/keaa025. [Epub ahead of print].
22. Wu D; Griffith JF; Lam SH; Wong P; Yue J, Shi L; Li EK; Cheng IT; Li TK; Hung VW; Qin L; Tam LS. Comparison of bone structure and microstructure in the metacarpal heads between patients with psoriatic arthritis and healthy controls: an HR-pQCT study. Osteoporosis Int 2020, doi:10.1007/s00198-020-05298-z.[**https://rdcu.be/b0m2a**](https://rdcu.be/b0m2a)
23. Tam LS. Approaches to screening for latent tuberculosis infection in patients with immune-mediated disease prior to commencement of biologics. Hong Kong Med J 2020 8(1):26-32.
24. Oliver S, Tam LS, Suet-Kei Kwok G, et al. The Asia-Pacific Initiative for Rheumatology Nurse Education: Current gaps, programme development and future outlook. Musculoskeletal Care. 2020;1–7. https://doi.org/10. 1002/msc.1473
25. Wu D, Li,C, Zhang S, Wong P, Cao Y, Griffith JF, Zhang X, Gu J, Tam LS.. Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis. Rheumatology 2020, in press.
26. TamLS, TanakaY, HandaR, Chang CC, Cheng YK, Isalm N, Li M, Lorenzo JP, Song YW, Yamamoto K, ZengX, Haq SA. Care for patients with rheumatic diseases during COVID-19 pandemic – a position statement from APLAR. IJRD 2020, May 27. doi: 10.1111/1756-185X.13863. Online ahead of print.
27. So H, Ng JW, Tam LS. No SLE with COVID-19 in Hong Kong: the effect of masking? J Rheumatol 2020, DOI: 10.3899/jrheum.200605
28. OliverS, TamLS, Suet-Kei KwokSK, Fusama M*,* Nakahara H, Zhang C, Yamamoto K, Furtner D. The Asia-Pacific Initiative for Rheumatology Nurse Education (ASPIRE): Current gaps, program development and future outlook. IJRD 2020, in press.

Others

1. Tam LS, Li EK, Tomlinson B. Modifiable Risk Factors for Premature Atherosclerosis in Systemic Lupus Erythematosus. Vas Dis Prev 2006;3: 61-72.
2. Lee VWY, Chan CW, Chan LH, Ng TS, Tam LS, Li EK, Lee KKC.  The Direct Medical Cost of Rheumatoid Arthritis in Hong Kong.  Journal of Medical Economics 2007;10(4):443-453
3. Kam KW, Tam MKP, Tam LS, Young AL. Infliximab in the Treatment of Refractory Ocular Inflammatory Diseases. Asia-Pacific Journal of Ophthalmology 2015;4:19-24.

Abstracts

### Li EK, Tam LS. [Bone mineral density in Chinese premenopausal females with systemic lupus erythematosus on long term corticosteroid therapy.](javascript:submit_form()) *Arthritis Rheum* 1998; 40 Suppl 9;S457.

### Tam LS, Li EK. Survival and predictor variables for mortality in systemic lupus erythematosus in Chinese. *Arthritis Rheum* 1998; 41 Suppl 9;S220.

1. Chan TH, Tam LS, Li EK. Salmonella infection in Chinese systemic lupus erythematosus (SLE) patients. *Arthritis Rheum* 1998; 41 Suppl 9;S331.
2. Tam LS, Li EK. [A review of 18 Chinese patients with primary pulmonary hypertension in systemic lupus erythematosus.](javascript:submit_form()) *Arthritis Rheum* 1998; 41 Suppl 9;S330.
3. Tam LS, Bruce IN, Fraser K, Gladman DD, Urowitz MB, Moldofsky H. Poor sleep efficiency in SLE is associated with previous neuropsychiatric involvement. *Arthritis Rheum* 1999; 42 Suppl 9;S1451.
4. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. [Early damage is a predictor of mortality in SLE.](javascript:submit_form()). *Arthritis Rheum* 1999; 42 Suppl 9;S 96.
5. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. [Coritcosteroid induced morbidity in SLE](javascript:submit_form()) . *Arthritis Rheum* 1999; 42 Suppl 9;S 96.
6. Li EK, Tam LS. Causes of death in 56 patients with systemic lupus erythematosus. *Ann Rheum* 2001; 60 Suppl 1;FR10099.
7. Chan RWY, Tam LS, Li EKM, et al. [Urinary inflammatory cytokine gene expression in lupus nephritis.](javascript:submit_form()) J Am Soc Nephrol 2002;13; S659A.
8. [Wong CK](http://apps.newisiknowledge.com/DaisyOneClickSearch.do?product=WOS&search_mode=DaisyOneClickSearch&doc=31&db_id=&SID=4EGIGBm@Ej4b6jLO8iK&name=Wong%20CK&ut=000224551400416&pos=1), [Lam CW](http://apps.newisiknowledge.com/DaisyOneClickSearch.do?product=WOS&search_mode=DaisyOneClickSearch&doc=31&db_id=&SID=4EGIGBm@Ej4b6jLO8iK&name=Lam%20CW&ut=000224551400416&pos=2), [Tam LS](http://apps.newisiknowledge.com/DaisyOneClickSearch.do?product=WOS&search_mode=DaisyOneClickSearch&doc=31&db_id=&SID=4EGIGBm@Ej4b6jLO8iK&name=Tam%20LS&ut=000224551400416&pos=3), [Ho CY](http://apps.newisiknowledge.com/DaisyOneClickSearch.do?product=WOS&search_mode=DaisyOneClickSearch&doc=31&db_id=&SID=4EGIGBm@Ej4b6jLO8iK&name=Ho%20CY&ut=000224551400416&pos=4), [Li EK](http://apps.newisiknowledge.com/DaisyOneClickSearch.do?product=WOS&search_mode=DaisyOneClickSearch&doc=31&db_id=&SID=4EGIGBm@Ej4b6jLO8iK&name=Li%20EK&ut=000224551400416&pos=5). Suppression of the chemokine expression by leflunomide in patients with rheumatoid arthritis (RA). Ann Rheum Dis 2003;62:S133.
9. Tam LS, Szeto CC, Li EK, et al. [Mesangial lupus nephritis in Chinese is associated with high rate of transformation](javascript:submit_form()). Ann Rheum Dis 2003;62:S434.
10. Tam LS, Li EK, Leung VYF, et al. [The effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: A double-blind, placebo-controlled pilot study](javascript:submit_form()). Ann Rheum Dis 2004;63:S212-213.
11. Tam LS, Li EK, Wong CK, et al. [Double blind, randomized, placebo controlled pilot study of leflunomide in systemic lupus erythematosus (SLE)](javascript:submit_form()). Ann Rheum Dis 2004;63:S213.
12. Tam LS, Chan AYK, Chan PKS, et al. [Higher prevalence of squamous intraepithelial lesion in systemic lupus erythematosus-association with human papillomavirus infection](javascript:submit_form()). Ann Rheum Dis 2004;63:S214.
13. Tam LS, Li EK, Wong CK, Lam CWK, Benzie IF, Tomlinson B, Leung PC. Safety and efficacy of Ganderma lucidum (Lingzhi) in rheumatoid arthritis(RA): a randomized conntrolled trial. *Arthritis Rheum* 2005; 52 Suppl 9:S552.
14. Tam LS, Li EK, Wong CK, et al. [Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory to traditional immunosuppressive therapy: An open-label trial.](javascript:submit_form()) *Arthritis Rheum* 2005; 52 Suppl 9:S195-S196.
15. Tam LS, Li EK, Tomlinson B. [Effects of infliximab treatment on insulin sensitivity and lipid profile in patients with active rheumatoid arthritis (RA)](javascript:submit_form()). *Arthritis Rheum* 2005; 52 Suppl 9:S347.
16. Lee VWY, Li EK, Tam LS, et al. [The direct medical cost of rheumatoid arthritis in Hong Kong](javascript:submit_form()). Value in Health 2005;8:SA27-28.
17. Li EK, Tam LS. [Efficacy of traditional Chinese acupuncture in the treatment of rheumatoid arthritis (RA): A double-blind controlled pilot study.](javascript:submit_form()) *Arthritis Rheum* 2006; 54 Suppl 9:S367-8.

CHAPTERS IN BOOKS

1. Li EKM, Tam LS. Systemic Lupus Erythematosus. In Sung JY, Wong LKS, Li PKT, Sanderson J, Kwok TCY (eds) *Principles and Practice of Clinical Medicine in Asia*, 2nd edn, pp.5974-609.Philadelphia: Lippincott Williams &Wilkins, 2002
2. Li EKM, Tam LS. Osteoarthritis. In Sung JY, Wong LKS, Li PKT, Sanderson J, Kwok TCY (eds) *Principles and Practice of Clinical Medicine in Asia*, 2nd edn, pp.663-667.Philadelphia: Lippincott Williams &Wilkins, 2002
3. Tam LS, Li EKM. Spondyloarthritis. In Sung JY, Wang JY, Shen T (eds) *Essential Internal Medicine*, pp 488-499. People’s Medical Publishing House 2009
4. Li EK, Zhu TY, Tam LS. Management of glucocorticoid-induced osteoporosis and fracture risk. In: Qin L. Orthopaedic Medicine: From Bedside to Bench to Bedside. 1st edition. Beijing , People’s Medical Publishing, 2012, page 559-71.

INVITED LECTURES (since Oct 2006)

**Hong Kong**

1. The third CUHK dermatology symposium 2006
2. The CUHK Diploma Program in Advances in Medicine 2006-2007
3. Postgraduate Programmes in Women's Health Studies CUHK since 2007
4. Rheumatology Core Course organized by the Hong Kong Society of Rheumatology – Sept 2007
5. Advances in clinical medicine -51ST anniversary scientific program organized by the Society of Physicians in Hong Kong in Dec 2007.
6. Huaxia Congress on Diagnosis and Management of Rheumatic Diseases in Hong Kong in Dec 2007
7. MSc in Sports Medicine and Health Science at CUHK since 2008
8. Rheumatology course for nurses – May 2008.
9. Latest update on Management of Rheumatoid Arthritis for Pharmacists – May 2008
10. Rheumatology Nurse Training Program organized by HA – Nov 2007.
11. Diploma in Advances in Medicine Programme, lectures on “SLE” and “CTD” on 17/8/08
12. Allied Health Professional refresher course on Sept 2, 2008.
13. Centre of Research and Promotion of Women’s Health 7th Annual Scientific Meeting on October 18, 2008. ‘Lupus in women: issues across the lifespan’
14. Talk for HK Society of Rheumatology Annual Scientific Meeting on “Premature atherosclerosis in rheumatic diseases” on 19/10/08
15. Lecture on “Therapeutic options in AS” for the workshop on Practical Use of Biological Agents in Rheumatology on Dec 12, 2008
16. Lecture on “Immune diseases & women's health’ for the Women's Health Studies Programme on 2 March, 2009
17. Lecture on “SLE” for the Master of Clinical Pharmacy Programme at CUHK in 31/3/09
18. Lecture on “Early rheumatoid arthritis – a curable disease?” for the society of physicians of Hong Kong on 26/4/09
19. Presentation on “Subclinical Carotid Atherosclerosis in Patients with Psoriatic Arthritis” at the Hong Kong College of Physicians Annual Scientific Meeting on 11 Oct, 2009.
20. Lecture for Master of Science in Cardiology 2009-2010 on “Cardiovascular manifestations in connective tissue diseases & potential management” on 3/11/2009, 4-6:30pm.
21. Lecture for 2009 Annual Conference on Medication Safety on “Important Drug Classes Causing Allergic Reactions – non-Aspirin NSAID” in the morning of 14 December 2009, HA Building, Argyle Street.
22. Women's Health Studies Programme on “ Biological causes of pain” on 3 Feb, 2010.
23. Lecture on “Update on treatment of inflammatory arthritis with biologic agents  
    Talk 1: TNF-alpha blockers” for Sunday Symposium of Society of Physicians Hong Kong (SPHK) (14 March 2010, 2-4:30pm)
24. Women's Health Studies Programme on “ Immune diseases & women's health” on e: 22 Mar, 2010
25. Lecture for the Joint immunology/rheumatology meeting on 17 April 2010 on “Innate immunity of HPV and SLE pathogenesis”
26. PsA TNF prospective study oral presentations (July12 14-15:30) at the Asia Pacific League Against Rheumatism (APLAR 2010) meeting.
27. RA and TB study oral presentations (July 13 14-15:30) at the Asia Pacific League Against Rheumatism (APLAR 2010) meeting.
28. Lecture on “Premature Atherosclerosis in Patients with Psoriatic Arthritis” at the Asia Pacific League Against Rheumatism (APLAR 2010) meeting on July 14, 2010.
29. PHAR 5887 Case Illustration seminar - SLE & Alkylosing Spondylitis -  
    Master of Clinical Pharmacy Nov 20, 2010
30. Centre of Research and Promotion of Women’s Health 10th ANNIVERSARY SYMPOSIUM 2011, 3 March 2011on “Autoimmune Disorder”
31. Chemical Pathology CUHK Departmental Seminar on “innate immunity in SLE. 20 May 2011.
32. 12th Regional Osteoporosis Conference (ROC 2011) on “Bone Microarchitecture in Systemic Lupus Erythematosus” on 22/5/2011 HKCEC
33. Ten Topics in Lupus on September 24 and 25 in Hong Kong on “SLE and HPV infection”
34. 2011 Joint Conference of Drug Safety Research Centres, 15 Novmeber 2011 on on "Allergic drug reactions to non-aspirin NSAIDs"
35. Hong Kong Society of Nuclear Medicine (HKSNM) Scientific Symposium on “Rheumatoid Arthritis: A Clinician's Perspective” 11 Mar 2012
36. AIM 2012 (2-3 June 2012) on “Premature atherosclerosis in rheumatic diseases”.
37. Orthopedics research seminar on “Steroid-induced osteoporosis in patients with systemic lupus erythematosus” on Aug 27, 2012 4-5:30 pm.
38. HK Allergy convention 15-16 Sept 2012 on “Allergic Reactions to commonly used drugs: Non-Aspirin NSAIDs” Sunday 16 September in the Plenary Symposium 3 on Rheumatology and Allergy during 9:15am to 10:30am.  It will be held in Room S221, Level 2 of the Hong Kong Convention and Exhibition Centre (old Wing), Wanchai.
39. AIM “SLE” and “CTD” on 4/11/2012
40. PHAR 5887 Case Illustration seminar - SLE & Ankylosing Spondylitis - Master of Clinical Pharmacy. Nov 17 (sat), 2:30-4:30pm
41. Lecture on “Rheumatology services in Hong Kong” and “Basic immunology of rheumatic disease” for the Post-registration Certificate Course in Rheumatology Nursing on 4/12/2012 10:00 am to 12:15 pm.
42. Lecture on “Common rheumatic diseases encountered” for the PWH course in Rheumatology Nursing 23/5/2013 1-2 pm.
43. AIM 29-30 June 2013 on “New SLICC SLE classification criteria”.
44. HKSR ASM 17/11/2013, Talk on “new criteria for SLE”.
45. Autoimmunity Congress Asia 21-23 Nov 2013 in Hong Kong. “Can suppression of inflammation prevent progression of premature atherosclerosis in rheumatic diseases?” Session Date: 11/21/2013, Session Time: 08:30 - 10:00 Duration: 15 mins.
46. “New Target in RA treatment: signaling pathway” 13:05-13:40 pm Nov 22, 2013. The New Era of Advance Therapy in RA management symposium during ACA 2013 congress.
47. The Society of Physicians symposium on ‘Risk and Prevalence of coronary artery disease in patients with collagen vascular disease’ in Mar 23 2014, 12-1 pm
48. Updates in Cardiology for Physicians and Allied Health Professionals 2014, 9:05-9:35am, 26 April 2014 (Saturday) on” improving prediction of atherosclerotic risk in patients with automimmune diseases”
49. RA - Disease Awareness Talk for General Physicians in Shatin Community Network Friday - 23 May, 2014, (Abbvie) entitled “New era of diagnosis and treatment of Rheumatoid Arthritis”
50. Orthopedics Monthly Research Seminar focusing on “Osteoporosis, Clinical Densitometry and Related Research” to be held at OLC Seminar, 1/F., LKSOPD from 1 to 1:15 pm on 27-May,2014. give a 15-min talk on “HR-pQCT study on SLE and Rheumatoid Arthritis”.
51. Advances in Medicine conference on 28-29 June 2014 (Sat-Sun). Lecture on “Understanding osteoporosis in rheumatic diseases beyond bone density - bone quality and strength”.
52. Patient Conference held at Polytechnic University on **20 July 2014 (Sunday)**.

We would like to invite you to be the guest at the opening ceremony of the conference and deliver a short speech to the participants.

1. Ustekinumab for Psoriatic Arthritis Advisory Board Meeting by Janssen either in The Mira (Tsim Sha Tsui) or Langham hotel (Mong Kok) on the evening of the 3rd of September between 6:30 pm – 8:30 pm, 8:30-9:30 Dinner
2. Diploma in Advances in Medicine 2014-2015. Date: 7 September 2014 (Sunday). Time: 3:15pm – 7:00pm. Venue: Kai Chong Tong, G/F., Postgraduate Education Centre, Prince of Wales Hospital, Shatin, N.T. Estimated no. of students: about 120 (60% Medical practitioners and 40% Para-medics) .Programme: Systemic Lupus Erythematosis (Prof. Lai-shan Tam) 5:15pm-7:00pm      Connective Tissue Diseases (Prof. Lai-shan Tam)
3. Interview by the media on rheumatoid arthritis for the 2014 Multimedia Awareness Campaign by HKARF on Oct 11, 2014
4. PHAR 5887 Case Illustration seminar - SLE & Ankylosing Spondylitis - Master of Clinical Pharmacy. Oct 17,2014 (tue), 6:30-8:30pm
5. Interview by the media HKAM-AM730 Article Contribution Invitation (HKCP 4th) 13 Oct 2014. On early rheumatoid arthritis.
6. Osteoporosis Society "G" symposium. Date: October or 25 2014, Title: Understanding glucocorticoid induced osteoporosis beyond bone density - bone quality and strength.
7. Lecture for the ARISE with APLAR symposium on “Understanding osteoporosis in rheumatoid arthritis beyond bone density - bone quality and strength” Nov 23, 2014
8. 19/1/2015 O& G conference 4:00 pm on “Severe complications from SLE and APLS” 16:40 – 17:20 organized by the Hospital Authority.
9. MSc Musculoskeletal Rehabilitation: Special Problems and Management Issues,  Topic:     Arthritides – inflammatory disorders of the joints and spine (about Rheumatoid Arthritis, Ankylosing Spondilitis & SLE) on 2-Feb-2015 .
10. MSc cardiology Tuesday, 12 May 2015, 3:00pm – 4:30pm (90 minutes) Shaw Auditorium, 1/F Postgraduate Education Centre, Cardiovascular Complication in Rheumatological Diseases organized by the CUHK
11. TVB program 快樂長門人21 May,2015 14:50-15:15 TVB city, Tseung Kwan O on PsA銀屑病關節炎
12. May 30 public talk on CV risk in PSA Time: 14:00-16:00, Venue: Seminar Room 1, 2/F., Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital. 銀屑病關節炎講座：如何減低心血管疾病風險?
13. 1/9/2015 (Tue) PsA patient talk, Jordan area, 突破中心. 7:30-9:30 on psoriatic arthritis, diagnosis and therapy organized by the Psoriatic arthritis patient group.
14. HKARF Lupus book interview Sept 18 12:30-2:00pm 10/F., Seminar Room
15. The Arthritides II C - Case Studies in Clinical Rheumatology Tutorial 11-Jan-2016(Mon) 2:30- 5:15pm
16. Interview by cable TV <至FIT男女》19 Jan 2016 11-12 noon on rheumatic diseases and CV risk, live interview on 21 Feb 2016
17. MSc/PgD in Musculoskeletal Medicine and Rehabilitation Topic:     Arthritides – inflammatory disorders of the joints and spine Date:       22-Feb-2016 (Mon)
18. “Multidisciplinary Approach to Chronic Disease Management” during “Enhancing Patient Centred Care through Improving Chronic Disease Management for Rheumatoid Arthritis: Collaboration and Exchange Expert Workshop” at Hong Kong on 10-11 May 2016 organized by the CUHK
19. Primary care education program: 21 May (Sat), 1:00pm-6:00pm, Kai Chong Tong , participants: 180 on “Spondyloarthritis for family physicians- when to refer ?” organized by the CUHK.
20. Lecture on “Improvement in the management of Psoriatic Arthritis’ organized by the Hong Kong Special Interest Group in Psoriatic Disease on May 28, 2016.
21. AIM 28-29 May 2016 on “Bone loss in rheumatoid arthritis – the role of HR-pQCT “ at HK organized by CUHK
22. Chairperson: 23/8 Roche symposium with Prof Bilijsma. 24/8 grand round and dinner.
23. Chairperson: 24/8/16: Medical ground around on rheumatoid arthritis: features,pathogenesis and treatment in 2016 . Time: 17:30-18:30. Venue: 2/F, Lecture Theatre, Lui Chi Wo Clinical Sciences Building, The Prince of Wales Hospital, Shatin, NT
24. Chairperson: Workshop for young rheumatologists and researches on 'how to publish a paper'. Time: 19:00-21:00 . Venue: Lobby Floor, Hyatt Regency Hong Kong, 18 Chak Cheung Street, Shatin
25. Speaker of Patient Conference on 27 August 2016 (Saturday) on 展望未來︰生物相似製劑的迷思, organized by the Hong Kong Arthritis Foundation.
26. AIM diploma course Topic: Systemic Lupus Erythematosus Date: 4 Sep 2016 (Sun) Topic 2 : Connective Tissue Diseases Date: 4 Sep 2016 (Sun)
27. Post-Registration Certificate Course in Advanced Medical Nursing (PRCC). Venue: PWH Auditorium, Date: 4 Oct 2016. Title:  Update on management of rheumatic disease – Psoriatic Arthritis (PSA) (13:00-14:00)
28. Oct 22nd, 2016 PHAR 5887 SLE & Alkylosing Spondylitis (430-630pm) – Case illustration
29. 4th Advances in Renal Biopsy Course PWH-CUHK Dec 7-10 2016
30. MSc/PgD in Musculoskeletal Medicine and Rehabilitation Topic:     Arthritides – inflammatory disorders of the joints and spine Date:       20-Feb-2017 (Mon) Time:      6:30pm - 9:30pm.Venue:   Prince of Wales Hospital, Shatin

**International Meetings**

1. Symposium on Advances in Internal Medicine 2007, Guangzhou, China
2. Oral presentation at the Annual European Congress of Rheumatology June 2008 on “Subclinical carotid atherosclerosis in patients with psoriatic arthritis”.
3. International conference in perinatal medicine 17-20 Oct, 2008 (in Macau) “Management of SLE complicating pregnancy” on Oct 17, 2008.
4. Lecture for Shanghai-HK Workshop on Rheumatology on “Premature atherosclerosis in rheumatic diseases” on 5-7/12/08.
5. Lecture on “Premature atherosclerosis for PsA” for Chinese Rheumatology Meeting 21-24 May 2009 in Shantung
6. Oral presentation on “ Natural History of Human papilloma virus and systemic lupus erythematosus” at European League Against Rheumatism Annual Meeting in Copenhagen -13/6/09
7. Lecture on **“**Human papilloma virus and systemic lupus erythematosus’ for the Guangdong – HK rheumatology meeting in Shenzhen on 3-5 July 2009
8. Oral presentation on “ Risk factors of squamous intraepithelial lesions in systemic lupus erythematosus” at the American College of Rheumatology Annual Meeting in Philadelphia -19/10/09
9. Annual scientific meeting of Sichuan rheumatism Association, Aug 19-21, 2010 in Chengdu on “premature atherosclerosis in psoriatic arthritis”.
10. oral presentations (July 13 14-15:30) at the Asia Pacific League Against Rheumatism (APLAR 2010) meeting on “Risk of TB in patients with RA”.
11. Lecture on “Premature Atherosclerosis in Patients with Psoriatic Arthritis” at the Asia Pacific League Against Rheumatism (APLAR 2010) meeting on July 14, 2010.
12. University of Toronto Lupus clinic 40th Anniversary Gala Celebration on “SLE and cervical diseases” April 1, 2011.
13. June 9-12, 2011 Prato, Italy: First International Cardiologist and Rheumatologist Focus on: ATHEROSCLEROSIS: A SHARED CONCERN. on: - "Evidence for accelerated atherosclerosis in Psoriatic arthritis and Ankylosing Spondylitis ".
14. July 14-16, 2011 Beijing, China: Huaxia meeting on: "Evidence for accelerated atherosclerosis in Psoriatic arthritis and Ankylosing Spondylitis ".
15. The **5th Autoimmunity Congress Asia** (ACA 2011), Singapore 17-19 November, 2011 on “Premature atherosclerosis for rheumatic diseases”
16. Excellence in Rheumatology Conference, Madrid, Spain from 25-28 January 2012, on “Cardiovascular complications of Ankylosing Spondylitis and Psoriatic arthritis”.
17. [International Federation of Psoriasis Associations](http://www.ifpa-pso.org/) (IFPA) and 3rd World Psoriasis & Psoriatic Arthritis Conference 2012 Stockholm, June 27-July 1, 2012 on “Psoriatic Arthritis in South East Asia: disease characteristics and economic burden”
18. APLAR 10-14 Sept 2012 on “Assessment and Outcome Measures in Psoriatic Arthritis " and " Overview of Psoriatic Arthritis Treatments: Now and the Future " on Thursday 13 September 2012
19. Teaching for Fudan University Sept 22, 2012
20. “Arise with APLAR”.- an APLAR education program. Shanghai 19th Jan, 2013. talk on osteoporosis.
21. 2013 Dr Stanley Ho Medical Development Foundation Symposium on 26-27th January 2013, in Macau (30 minutes including Q&A), in either English or Cantonese, on "Updates on Management of Rheumatological Diseases"
22. Keynote speaker to attend the upcoming 2013 Annual Scientific Conference of Jiangsu Society for Rheumatology being held in Wuxi, Jiangsu province from April 19 to 21, 2013 on “ Can suppression of inflammation prevent progression of premature atherosclerosis in rheumatic diseases?”.
23. Chinese Rheumatology Association (CRA) annual conference at Lanzhou 16th to 18th of May 2013. PPT by the end of March, 2013. short biography and a recent photo. “Understanding osteoporosis in rheumatic diseases beyond bone density- bone quality and strength"
24. EAGOR meeting 31/5/2013-1/6/2013 “DKK-1 AND RANKL/OPG PREDICT CHANGES IN BONE MINERAL DENSITY AND BONE MICROSTRUCTURE IN SLE ON LONG-TERM GLUCOCORTICOID: A PROSPECTIVE STUDY”
25. APLAR 2013 30 Aug to 1 Sept 2013 at Bali on “Understanding pathogenesis of Osteoporosis beyond the Bone mineral - Bone architecture”
26. GD-HK symposium 2013 in Guangzhou. The tentative date will be on September 28 entitled “Understanding osteoporosis in rheumatic diseases beyond bone density - bone quality and strength”.
27. Fo Shan annual meeting of Rheumatology, we are pleased to invite you to attend the meeting on 13-14 Dec, talk on premature atherosclerosis in rheumatic diseases.
28. APLAR 2014 lunch symposium 2-4/4/2014 on “long-term efficacy of anti-TNF in HK”
29. Janssen “Mission Remission workshop” Sunday 11th May 2014 in Kuala Lumpur on “Managing for long term CV outcomes of RA”.
30. 12-13 July,2014 Forum of Progress in Rheumatology organized by Guangdong Provincial Hospital of Chinese Medicine "风湿病诊治进展及中医特色治疗技术培训班", which is a national program of further education for medical doctors (No.2013290202043) and will be held in Guangzhou. Title: . “Can suppression of inflammation prevent progression of premature atherosclerosis in rheumatic diseases?”
31. 6th International Forum on Rheumatoid Arthritis (IFRA 2014), Beijing, China from September 20-21, 2014. Talk on “Understanding osteoporosis in rheumatoid arthritis beyond bone density - bone quality and strength”
32. IBDW 2014 in Oct 13-17. “HR-QCT in clinical rheumatoid arthritis”.
33. Taiwan Rheumatology Association annual conference on “glucocorticoid-induced osteoporosis”, 6-7 Dec, 2014 (Saturday & Sunday). “Understanding glucocorticoid induced osteoporosis beyond bone density - bone quality and strength” The plenary lecture session of “Glucocorticoid-Induced Osteoporosis” will be held in the afternoon of 6 Dec, 2014 (Sat.).
34. Speaker at a round table event at Macau on the 17th of July to talk about “PSA disease and current treatment options” by Macau Physician Society.
35. APLAR 2015 in Chennai, India, from 6 - 9 September 2015. Speaker on “RA with Chronic Kidney Disease”
36. 廣東省醫學會風濕病學術年會暨第九屆粵港風濕病學研討會上作專題報告 Annual Meeting of Guangdong Medical Association of Rheumatology 2015 & 10th Guangdong-HongKong Symposium of Rheumatology on “Providing quality care to rheumatology patients- can our dreams come true? On 2015年9月25日-26日 in Guangzhou, China, organized by the Guangdong Medical Association of Rheumatology
37. The International Congress of Chinese Nephrologists ICCN 2015 Date: 13 Dec 2015 Time: 1600hrs – 1715hrs, Theme: Lupus nephritis – basic research Lecture Title: Novel biological agents for lupus nephritis Presentation Duration: 20 minutes organised by the Hong Kong Society of Nephrology
38. 9th IM Summit March 4-6 2016. Lecture on “CDM experience from PWH” organized by Xian Janssen Pharmaceutical Limited. Guangzhou, China.
39. Renji 2016 Arthritis Workshop as a keynote speaker on “Bone loss in rheumatoid arthritis – the role of HR-pQCT “ in this 23-25 April, Shanghai , organized by Shanghai Jiao Tong University.
40. Taiwan speaker tour May 14-16 , 2016, on “The importance of early diagnosis and treat to target in PsA” organized by Janssen Taiwan
41. 2016 International Symposium of Ankylosing Spondylitis/ Spondyloarthritis in China”, on Jul 16, 2016 in Guangzhou on “premature atherosclerosis in spondyloarthritis” organized by the Third Affiliated Hospital of Sun Yat-sen University at Guangzhou , CHINA
42. APLAR 26-29 Sept 2016. Chairperson of the APLAR 2016 The Janssen lunch symposium will be on the 28th Sep, Wednesday, 12.15pm – 1.45pm. The title of our symposium is “Managing RA for Life: Applying the principles of chronic disease management”.
43. Lecture Session: PSA Session Date: September 28 2016 Session Time: 16:00-18:00 Title: Management of PsA: Clinical Assessment and Co-morbidities.
44. ACR November 11 - 16, 2016. ACR 2016 study group "Best practices in fracture prevention" . Lecture on "Assessment of fracture risk beyond bone mineral density- bone architecture and strength using HR-pQCT"? This session will focus on the utility of a new technology -  high resolution peripheral quantitative computed tomography - on the assessment of volumetric bone mineral density, architecture and strength on fracture risk in patients with osteoporosis.
45. ICCR 26-27 November 2016 Date: Day 1 (26 November) Time: 10:00–11:00 Session Name: Plenary Lecture 2 – Psoriatic Arthritis Lecture Title: Premature Atherosclerosis in PsA – the Role of Inflammation

RESEARCH INTERESTS:

1. Bone loss in patients with rheumatic diseases.
2. Risk factors for premature atherosclerosis in systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis.

CONTINUING MEDICAL EDUCATION

1. Basic Practical Statistics for Medical Research organized by centre for clinical trials and epidemiological research, Chinese University of Hong Kong. Total 18 hours. Oct – Nov 1997
2. Short course in outcomes and effectiveness research 1998. Co-organized by Department of Community and Family Medicine, the Chinese University of Hong Kong and School of Hygiene and Public Health, Johns Hopkins University.

10-12 July 1998

1. Chinese University of Hong Kong Fundamental Critical Care Support course.

6-7 July 2002

SERVICES TO COMMUNITY

1. Professional advisor of the Hong Kong Society for Rehabilitation Community Rehabilitation Network June-2007- March 2016
2. Honorary Advisor of the Hong Kong Society for Rehabilitation Community Rehabilitation Network 1 April 2016 to 31 March 2018
3. Honorary member of the Hong Kong Lupus Association Dec-2007-
4. Professional advisor of the Hong Kong Ankylosing Spondylitis Association

March2009-

1. Honorary advisor of the B27 Association 2013-2015
2. Panel of experts to provide expert opinions on consultation or referral for Equal Opportunities Commission (on behalf of the Faculty of Medicine of the CUHK) since Oct 2019